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Chronic myeloid leukemia (CML) is caused by the constitutive tyrosine kinase 
activity of the oncoprotein Bcr-Abl.  This aberrant kinase activity activates a multitude of 
oncogenic signaling pathways resulting in myeloid cell proliferation.   In the early 2000s, 
the development of tyrosine kinase inhibitors (TKIs) (such as the breakthrough drug 
imatinib) greatly improved the prognosis and overall survival of those diagnosed with 
CML.  However, point mutations in the TK domain often limit the clinical effectiveness of 
TKIs.  Second- and third-generation TKIs have been developed to treat those with mutant 
Bcr-Abl; however, off-target effects and subsequent toxicity of these newer drugs limits 
their use. 
 The N-terminal coil-coiled (CC) domain of Bcr-Abl allows for 
homooligomerization, a prerequisite to aberrant TK activity.  Previous work in the lab has 
focused on designing a mutant CC which is capable of binding to the CC in Bcr-Abl, 
thereby inhibiting oligomerization and subsequent oncogenic signaling.  The lead 
construct, the 72-amina acid CCmut3, was effective against cells harboring both wild-type 
and clinically-relevant Bcr-Abl mutants when delivered as a gene.  As gene therapy is still 
preclinical, the aim of this work was to create a translatable version of CCmut3.  In one 
study, a leukemia-specific cell-penetrating peptide was added to the N-terminus of the CC, 
which facilitated protein delivery to leukemic cells and subsequent induction of apoptosis 
in Bcr-Abl+ cells. Next, peptide stapling was implemented in an attempt to create a 
iv 
proteolytically-resistant version of CCmut3. Locking the peptide backbone of an α-helical 
peptide with an all-hydrocarbon staple can lead to increased helicity, target affinity, serum 
stability, and half-life.   However, stapling of CCmut3 paradoxically led to increased 
sensitivity to proteolysis, which is explored in Chapter 4. The last chapter in this 
dissertation focuses on the use of alternative staples and other modifications that could be 
used to design CC constructs that are resistant to proteolysis. 
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BACKGROUND AND SIGNIFICANCE 
 
Summary 
 Chronic myeloid leukemia (CML) is caused by the oncoprotein Bcr-Abl, created 
by a reciprocal chromosomal translocation resulting in a truncated chromosome 22, known 
as the Philadelphia chromosome (Ph).  The fusion protein Bcr-Abl activates numerous 
oncogenic signaling pathways through a constitutively active tyrosine kinase (TK) domain, 
resulting in cell growth and survival. Conventional therapies target this TK domain, 
inhibiting the kinase activity and subsequent downstream signaling.  While these ‘tyrosine 
kinase inhibitors’ (TKIs) have converted CML from a deadly cancer to a chronic condition, 
mutations in the TK domain often leave these TKIs ineffective.  Second and third 
generation TKIs have been developed to treat those with mutated Bcr-Abl, but off-target 
effects limit their use.   Another class of resistance, known as Bcr-Abl-independent 
resistance, appears in the absence of TK domain mutations, and is especially difficult to 
treat.  
 Bcr-Abl oligomerization through an N-terminal coiled-coil (CC) domain is a 
prerequisite to the aberrant kinase activity of Bcr-Abl. Indeed, previous work has shown 
that removing this oligomerization domain abolishes the oncogenic activity of Bcr-Abl.  
Previous work in the lab focused on creating a mutated version of this CC (known as 
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CCmut), which would preferentially bind the CC in Bcr-Abl while avoiding homo-
oligomerization.  This CCmut was effective against both wild-type and clinically-relevant 
Bcr-Abl mutants.  However, this work was all performed using gene delivery (transfection, 
lentiviral infection).  Chapters 2-5 focus on translating CCmut3 into a deliverable, 
biologically stable protein, utilizing cell-penetrating peptides (Chapters 2 and 3) and 




The Breakpoint Cluster Region 
 
 The breakpoint cluster region gene (BCR) is located on the long arm of 
chromosome 22, specifically 22q11. While the Bcr protein is involved in development, its 
functions in adult organisms are unclear. For instance, BCR-knockout mice develop with 
only mild cognitive impairment and neutrophil development [1, 2]. In adults, Bcr protein 
levels are highest in the brain and hematopoietic cells, specifically during the early stages 
of myeloid differentiation [3]. Bcr and homologous protein Abr are now believed to play a 
role in cell polarity, inflammation, memory, and may even be involved in bipolar disorder 
[4-7]. 
The ubiquitously expressed Bcr protein is almost entirely cytoplasmic,  and is 
involved in G protein signal transduction pathways, trafficking of growth factors, and 
mediating transcription through peroxisome-proliferator-activated receptor gamma [1, 3, 
4].  Specifically, the C-terminal region of the Bcr protein activates guanosine triphosphate 
hydrolyzing enzymes (GTPases), also known as GTPase-activating proteins (GAPs) 
(Figure 1.1) [3, 8].  Bcr accelerates the GTPase activity of RAC1, a family of proteins that 
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link extracellular signals to cellular responses, including cytoskeletal reorganization and 
subsequent membrane ruffling [3].  RAC1 binding to Bcr and subsequent activation 
requires the GAP domain of Bcr first bind GTP [9]. While this region is important in the 
endogenous activity of Bcr, the RAC-GAP domain is lost upon recombination with the 
ABL1 gene [10].  Bcr also associates with the xeroderma pigmentosum protein (XPB) via 
its DH/PH domain (Figure 1.1), which is involved in DNA repair, cell cycle regulation, 
and the initiation of transcription [3]. 
 The BCR gene contains 23 exons, and its transcripts are either 4.5 or 7.0 kilobases 
(kb) in length [3].  The 5’ untranslated region (5’ UTR) containing the transcription 
regulatory regions are important, as this same region will control the transcription of the 
fusion gene BCR-ABL1 [3].  The two resulting proteins are 130 and 160 kilodaltons (kDa), 
respectively, with the 130kDa protein being primarily nuclear, and the 160 kDa protein 
cytoplasmic [3]. 
Structurally, the Bcr protein contains a number of domains, including N-terminal 
oligomerization domain, serine/threonine kinase domain, Src homology (SH2)  binding 
domain, Dbl homology domain (DH), Pleckstrin homology domain (PH), also known as 
the Rho GTPase-specific guanine nucleotide exchange factor (RhoGEF) (Figure 1.1) [3].  
At the N-terminus of the protein is a coiled-coil (CC) oligomerization domain, which 
interacts with F-actin and is thought to be required for the cytoplasmic location of Bcr and 
the fusion protein Bcr-Abl [3, 11]. This will be discussed in detail later in this chapter, as 
will the activity of the DH/PH domain.  The serine/threonine kinase domain can both auto- 







Figure 1.1 Bcr protein domains and select functions. Starting with the N-terminus, 
domains include the coiled-coil (CC) oligomerization domain, serine/threonine kinase 
domain, DH/PH and RhoGEF domains, and finally the Rac-GAP domain.  Phosphorylation 
of the serine/threonine kinase domain at tyrosine-177 allows binding of the adaptor protein 
Grb2 (via SH2 domains) and subsequent Ras signaling.  The DH/PH domain binds the 
xeroderma pigmentosum protein (XPB), which is involved in transcription initiation and 
DNA repair. Finally, the RhoGEF and Rac-GAP domains work together to inactivate Rac. 
Abbreviations: CC, coiled-coil; S/T, serine/threonine; DH/PH, Dbl homolgiy/Pl; GEF, 
GTPase-specific guanine nucleotide exchange factor; GAP, GTPase-activating protein; 









in the SH2 binding domain permits Bcr to interact with the adapter protein Grb2 which 
subsequently binds Son of Sevenless (SoS), resulting in increased Ras signaling [3, 13].  
SH2 binding domains are highly conserved sequences of approximately 100 amino acids 
that bear no catalytic activity [3].  The SH2 binding domains of Bcr are different from other 
SH2 domains in that those in  Bcr can bind SH2 binding sites with phospho-serine and 
phospho-threonine, as well as the standard phospho-tyrosines [3].  The Rac-GAP domain 
is important in the negative regulation of Rac and Cdc42, and along with the RhoGEF 
domain converts Rac from the active (Rac-GTP) to inactive (Rac-GDP) form [9].  Loss of 
Bcr Rac-GAP function in vivo results in severe inflammatory response to 
lipopolysaccharides as well as increased ROS production by neutrophils  innate immune 
responses in mice, [14] while in vitro experiments noted increased actin reorganization and 
membrane ruffling [15].   
 
Abelson Tyrosine-Protein Kinase 1 (ABL1) 
 Cellular Abelson protein tyrosine kinase (c-Abl) is encoded by the ABL1 gene, 
closely related to the Src family of kinases [16]. Located on the long arm of chromosome 
9 (9q34) [3], this 140 kDa ubiquitously-expressed nonreceptor tyrosine kinase is found 
both in the cytoplasm and nucleus, as it often shuttles between the two compartments via 
myristoylation and regulation of its nuclear localization (NLS) and nuclear export signals 
(NES) [2, 17-19]. Unlike BCR1 knockouts, ABL1 knockouts clearly suffer developmental 
anomalies; these mice have increased perinatal mortality, lower birth weight, deficient 
bone and leukocyte development, and suffer from abnormal head and eye development [2, 
17, 20].   
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Cytoplasmic c-Abl is commonly activated by numerous surface receptors, 
including platelet-derived growth factors receptors (PDGFR), cadherins, neurotrophin 
receptors, and other ligand-gated ion channels [17].  Nuclear c-Abl is involved in a myriad 
of proapoptotic functions. When in the nucleus,  c-Abl is involved in responses to 
genotoxic stress and cell cycle progression  [17].  Specifically, DNA damage activates c-
Abl, which in turn regulates the PI3K-related proteins ATM and ATR and their substrates 
Chk1 and Chk2 [21], resulting in cell cycle arrest, DNA repair, or apoptosis [22].  
Additionally, c-Abl is known to be involved in the regulation of caspase cleavage, a key 
stage of apoptosis induction [23].  The stark differences between pro-apoptotic c-Abl and 
antiapoptotic Bcr-Abl will be discussed in the next section. 
The kinase activity of c-Abl is negatively regulated by myristoylation of its N-
terminal ‘cap’ region [16] (Figure 1.2B).  Upon myristoylation, this cap is buried in the 
kinase domain, thus inhibiting kinase activity [19].  Further, this causes the SH2 and SH3 
domains of c-Abl to form an inhibitory scaffold that holds the protein in this inactive state 
[17].  This regulatory cap is lost upon fusing with BCR1 (Figure 1.2 A and C), and is 
generally responsible for the increased kinase activity of Bcr-Abl compared to that of c-
Abl (discussed in detail in the next section) [19].  It is likely that ligand binding to the 
SH2/SH3 domains releases them from their inhibitory binding state, but further tyrosine 
phosphorylation of c-Abl (including, but not limited to Y412) is necessary for its kinase 
activity [17].  When unbound, the SH2 and SH3 domains are free to bind cell surface 
receptors, which regulate c-Abl activity [17].    
C-terminal to the SH2 domain is the tyrosine kinase domain and active site (Figure 









Figure 1.2: Bcr-Abl domains and signaling. A) Bcr protein domains.  B) c-Abl protein 
domains. The dotted red line represents the location of the reciprocal translocation between 
chromosomes 9 and 22, which results in the creation of C) Bcr-Abl. D) downstream 
signaling of Bcr-Abl. Dashed lines represent indirect interactions. 
Abbreviations: CC, coiled-coil; S/T, serine/threonine; DH/PH, Dbl homolgiy/Pl; GEF, 
GTPase-specific guanine nucleotide exchange factor; GAP, GTPase-activating protein;      
SH, Src Homology domain; Y-kinase, tyrosine kinase; NLS, nuclear localization signal; 
DBD, DNA binding domain; ABD, actin binding domain; NES, nuclear export signal; 








with  deformed   DNA   in   a  sequence-dependent   manner [24].  Finally,  the   C-terminus  
contains an F-actin binding domain for direct binding the cytoskeleton, which is 
uncommon in tyrosine kinases [17].  Binding interactions between c-Abl and F-
actin/microtubules may also partially regulate c-Abl activity [17].   See Figure 1.2 B for 
domain positions in c-Abl. 
 
Bcr-Abl 
 A head-to-tail reciprocal translocation between BCR and ABL1 on chromosomes 
22 and 9, t(9;22)[q34.1;q11.21] creates the fusion gene BCR-ABL1, which encodes for the 
Bcr-Abl protein, responsible for chronic myeloid leukemia (CML) (Figure 1.2C) [3].  The 
result, a truncated chromosome 22 known as the ‘Philadelphia chromosome’ (Ph), was first 
discovered and associated with CML in 1960[25], and a more precise understanding of the 
reciprocal translocation was published by Janet Rowley in 1973 [26].  However, it was not 
until 1990 that studies confirmed Ph is the causative agent of CML [27, 28]. Bcr-Abl is 
now known to be necessary and sufficient to cause CML.  That is, the expression of Bcr-
Abl in normal hematopoietic stem cells is sufficient to induce a CML phenotype [27, 28].  
While this work is primarily concerned with Bcr-Abl as it relates to CML it is important to 
note that 20% of adult and 5% of pediatric acute lymphoblastic leukemias (ALL) are Ph+ 
[3].    
 The translocation sites of both BCR and ABL1 contain the Alu transposable repeat 
sequence, the sites of translocation.  Chromosomes 9 and 22 are in close proximity during 
the S to G2 transition, which is likely partially responsible for the increased frequency of 
this specific translocation event [3].  While the break occurs in only one region in ABL1 
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(C-terminal of the cap), BCR has two known break points.  Therefore, the Bcr-Abl protein 
is typically 190 or 210 kDa, depending on the site of recombination in Bcr [3]. While p210 
is typically seen in CML, p190 Bcr-Abl is more common in acute leukemias and is 
generally more active than p210 Bcr-Abl [3].  In both cases, the resulting proteins contain 
the N-terminal oligomerization domain of Bcr and have constitutive tyrosine kinase 
activity (Figure 1.2D) [3].   
 The Bcr-Abl fusion protein contains most of the same domains present in both Bcr 
and c-Abl, but the C-terminus of Bcr and the N-terminus of Abl is lost (Figure 1.2).  The 
N-terminus of c-Abl plays a key role in tyrosine kinase autoregulation, and its loss is 
partially responsible for the constitutive tyrosine kinase activity of Bcr-Abl [25].  While c-
Abl is primarily a nuclear protein, the fusion protein Bcr-Abl is wholly cytoplasmic [29]. 
The N-terminus of Bcr-Abl includes the coiled-coil (CC) oligomerization domain, which 
is the major target throughout this dissertation [25]. Next is the  serine/threonine kinase 
domain (discussed earlier), as well as the Dbl homology/Pleckstrin homology (DH/PH) 
domain.  While the DH/PH domain is present in p210 Bcr-Abl, its absence in p190 Bcr-
Abl suggests it plays a role in cellular adhesion, as its absence results in the release of 
immature lymphocytes from bone marrow [3, 30]. 
 Following the breakpoint are the SH2 and SH3 domains of c-Abl (Figure 1.2c). C-
terminal to the SH2 domain is the tyrosine kinase of c-Abl.  Beyond the loss of inhibition 
caused by deletion of the regulatory cap of c-Abl, Bcr-Abl dimerization and subsequent 
tetramerization further increases the kinase activity.  While the CC domain will be 
discussed in detail later, the following is a brief overview.  The N-terminal CC domain 
enables antiparallel dimerization of 2 Bcr-Abl proteins, which is then followed by the 
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tetramer formation of a dimer of dimers [31, 32].  This orientation allows for the 
transautophosphorylation of tyrosine residues in the Bcr and c-Abl portions of the protein 
[17, 33].  Both the altered location of c-Abl and its tyrosine kinase activity are responsible 
for the oncogenic activity of Bcr-Abl [29].  The downstream targets of Bcr-Abl are 
discussed in the next section. 
 
Downstream Targets of Bcr-Abl 
 The cytoplasmic nature of the fusion protein Bcr-Abl allows it to bind with many 
proteins not normally recognized by the primarily-nuclear c-Abl. Bcr-Abl requires 
phosphorylation of Y245 and Y412 for kinase activity [34].  While c-Abl contains the 
constitutively active tyrosine kinase, much of this kinase activity is targeted towards Bcr 
[35].  As stated above, phosphorylation Y177 in Bcr creates a Grb2 binding site.  This 
adapter protein is the base of a protein complex including Bcr-Abl, Grb2, GAB2, and SoS 
[36].  This complex in turn activates many antiapoptotic, progrowth, and prosurvival 
pathways and proteins, including Ras, AKT, Janus kinase (JAK2 and 1), STAT5/3 and 
PI3K (Figure 1.2D) [36].  Although the relative importance of each of these pathways to 
Bcr-Abl oncogenesis is unclear, Ras signaling is a prerequisite to Bcr-Abl-mediated, 
growth-factor-independent growth and survival [3, 19].  Further, the transcription factor 
STAT5 is necessary for both initiation and maintenance of oncogenesis in CML, and its 
activation is mediated via kinase activation of src family kinases (SFC)  [19].  Bcr-Abl 
positive cells have also been shown to have increased levels of the antiapoptotic proteins 
Bcl-2 and phospho-BAD [3].  Taken together, alterations in these proteins/pathways result 
in decreased cell adhesion, increased mobility, decreased apoptosis, and increased cell 
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proliferation [3, 25, 37].  Next, the disease caused by Bcr-Abl – chronic myeloid 
leukemia—will be discussed. 
 
Chronic Myeloid Leukemia 
 CML is generally considered a triphasic disease: chronic phase, accelerated phase, 
and blast crisis. Today, approximately 90% of patients who are diagnosed with CML are 
in the chronic phase [38].  Patients diagnosed in chronic phase typically present with vague 
symptoms, such as fatigue, weight loss, abnormal bleeding, splenomegalay, and/or 
leukocytosis [39].  Diagnosis is confirmed by cytogenic analysis and the presence of the 
Ph chromosome [38].  The chronic phase is defined by the presence of <10% blastic cells 
in the peripheral blood or bone marrow [38].  If left untreated, patients will progress into 
the accelerated disease phase within 2 years, and then rapidly move into the fatal blast crisis 
[40].  Patients in the accelerated phase have increased basophils and blastic cells in 
peripheral blood, as well as persistent splenomegaly [38].  Finally, blast crisis is defined 
by an increase number of blasts (>30%) in bone marrow and extramedullary disease, with 
typical sites including bone, lymph nodes, skin, and soft tissue [38].  The molecular 
mechanisms of progression are not fully understood, but are thought to involve genetic 
instability of Ph+ cells, resulting in gene duplications, mutations, and rearrangements, 
many of which affect p53 or retinoblastoma (Rb) pathways [41, 42]. 
 An estimated 70,000 people live with CML in the United states [43], with over 
8,000 new cases estimated for 2016. [43].  While the median age at diagnosis is 64, 10% 
of patients are diagnosed before the age of 35, and 35% are diagnosed before 55 [43]. Due 
almost entirely to the development of tyrosine kinase inhibitors (TKIs) (discussed in the 
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Although CML was first characterized in 1845, the first breakthrough TKI was not 
approved until 2001 [25].  Prior to this, nonspecific anticancer drugs such as the alkylating 
agent busulfan or the ribonucleotide reductase inhibitor hydroxyurea were given to patients 
[44].  Hydroxyurea was shown to increase overall survival (OS) compared to either 
busulfan or placebo, while busulfan showed no improvement in OS compared to placebo 
controls [44, 45]. Allogenic bone marrow transplant (BMT) was the treatment of choice 
for healthy individuals, and it is still the only curative treatment for CML [46].  However, 
due to the risks, today BMT is reserved for patients refractory to TKI therapy [46]. 
 Interferon α, first used to treat myeloid malignancies in the 1970s, was another 
popular therapy before the development of TKIs [47].  Although it was used extensively 
throughout the 80s and 90s, it was only approved as a first-line agent for CML in 1995 
[47].  Interferon α2A demonstrated increased OS and event-free survival over both 
busulfan and hydroxyurea [47].  However, adverse effects associated with interferon, such 
as severe fatigue, neurotoxicity, and liver function abnormalities, curbed its use [47].   This 
was partially overcome by PEGylated versions of interferon α (Pegasys®, and PegIntron®) 
which are better tolerated than naked interferon α.  Interferon α has many mechanisms of 
action, and the individual importance of any one of these is unclear [47].  Broadly, 
interferon α can induce apoptosis through Jak/STAT pathway, arrest cells in G1, suppress 
angiogenesis, activate immune effector cells, suppress hematopoiesis, and increase cell 
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adhesion [47].  While largely replaced by TKIs, interferon α is being investigated in 
combination with these TKIs, as the combination has the potential to cure a subset of 
patients [47, 48]. 
Omacetaxine (Synribo®), a protein translation inhibitor, was approved in 2012 for 
use in refractory CML.  While omacetaxine has been shown to marginally benefit those 
with refractory CML (including those with T315I), the ubiquitous nature of serious adverse 
events (seen in 99% of patients) curtails its use [49]. 
 
Tyrosine Kinase Inhibitors 
 The breakthrough drug imatinib (Gleevec®), approved in 2001, selectively inhibits 
the tyrosine kinase of c-Abl and Bcr-Abl [47].  Originally identified in a screen for 
inhibitors of protein kinase C, whose catalytic site closely resembles that of c-Abl [26], the 
molecule was then modified to 1) abolish PKC inhibition while maintaining Bcr-Abl 
inhibition, and 2) improve aqueous solubility and bioavailability [26].  Imatinib is known 
to interact with the nucleotide binding site of Abl when it is in the inactive, closed 
formation [26, 50, 51].  In vitro, imatinib inhibits Bcr-Abl autophosphorylation as well as 
phosphorylation of downstream targets at submicromolar doses [47]. Once shown superior 
to interferon α in the IRES trial, imatinib was approved and quickly became the first-line 
therapy of choice [47, 50]. 
 While treatment with imatinib is typically initially effective, resistance may 
develop, leaving patients in need of alternative therapies.  Various mechanisms of 
resistance will be discussed in the next section, but briefly, it is common that mutations 
in/near the Abl tyrosine kinase domain can preclude drug binding while leaving the 
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catalytic activity of the pocket unaltered [51].  For this reason, the second generation TKIs 
nilotinib (Tasigna®) and dasatinib (Sprycel®) were developed.  Nilotinib is based on the 
imatinib structure, but was designed to be a more potent inhibitor [51].  Dasatinib, 
originally designed to inhibit Src kinases, is a competitive inhibitor of the ATP binding 
site, and thus binds Bcr-Abl in the active conformation [52, 53].  While these two drugs 
did much to help those with imatinib-resistant CML, further Bcr-Abl kinase domain 
mutations often develop, leaving these second generation drugs ineffective, especially 
against T315I mutants and compound mutants [54]. Bosutinib, another dual Src/Abl1 
kinase inhibitor, which binds to Bcr-Abl in a unique manner, has different resistance 
profiles from all of the previous three TKIs [55].  Ponatinib (Tasigna®) was developed 
specifically to target the T315I ‘gatekeeper’ mutation [55].  This mutation both disrupts 
hydrogen binding of the TKI, and also biases the kinase towards the active state [55]. 
However, the modifications that allow ponatinib to inhibit T315I Bcr-Abl also cause it to 
inhibit multiple off-target kinases, such as those in the hedgehog pathways, GFGP, and 
Src-family kinases [51]. Indeed, ponatinib was temporarily removed from the market due 
to unacceptable, serious cardiovascular events, likely linked to the nonspecific nature of 
ponatinib, and has a black box warning [52].  Due to the clonal nature of CML, many 
researchers believe resistance to all TKIs is inevitable [56]  Table 1.1 shows the different 
TKIs and efficacy against Bcr-Abl tyrosine kinase domain mutations [52, 57, 58].   
Nilotinib, dasatinib, and imatinib are now all approved as first-line therapy, leaving 
clinicians with much to consider.  The second-generation drugs produce higher molecular 
and cellular responses compared to imatinib, but none has shown superior long-term 
survival [59].  These drugs are generally well tolerated, but they are not without their  
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Table 1.1 Bcr-Abl mutations and clinical effectiveness of approved TKIs.  Warm 
colors (green) represent sensitivity to the particular TKI, while cold colors (red) denote 








adverse events.  Indeed, in the initial phase III trial of imatinib, 14.3% of patients 
discontinued therapy due to adverse drug events [60].  Each TKI has its own unique side 
effect profile (Table 1.2), and this information is commonly used when starting/changing 
a patient’s TKI [52, 61]. 
 
Allosteric Inhibitor 
ABL001, currently in clinical trials, binds the pocket in c-Abl normally filled by its 
own myristoylated N-terminal cap [62]. This causes a conformational change, ablating the 
Y-kinase activity of c-Abl.  In vitro and in vivo, ABL001 is effective against nearly all 
tested tyrosine kinase mutations, including T315I.  However, mutations that preclude 
ABL001 from binding Bcr-Abl have been discovered.  Mice treated with ABL001 alone 
had complete tumor regression, but relapsed within 60 days of the termination of treatment.  
However, mice treated with the combination of nilotinib and ABL001 showed no signs of 
disease relapse, up to 150 days after the end of treatment, thus suggesting these two drugs 
may be used synergistically (as in this ongoing clinical trial) [62]. Serious ADEs include 
anemia, neutropenia, and increased lipases, which caused 10% of patients in the phase 1 
trial to discontinue therapy (ref).  Overall, ABL001 is a promising new therapeutic, 
although its place in therapy is yet to be determined. 
 
Resistance 
 It is estimated that up to 1/3 of patients who start on imatinib will not achieve their 
therapeutic goals, known as ‘primary resistance’ [63].  However, point mutations were 











      
imatinib 
Rash, decreased LVEF, CHF, arterial thrombotic events, 
noninfectious pneumonitis/diffuse alveolar damage/pulmonary 
fibrosis, mucositis/stomatitis, diarrhea/colitis, neutropenia, 




Rash, decreased LVEF, CHF, QT prolongation, arterial thrombotic 
events, diarrhea/colitis, hyperglycemia, neutropenia, 
thrombocytopenia, transaminase elevations, hyperlipasemia, 
hypophosphatemia 
BBW: Life-threatening heart problems, sudden death 
 
dasatinib 
Rash, decreased LVEF, CHF, QT prolongation, arterial thrombotic 
events, noninfectious pneumonitis/diffuse alveolar 
damage/pulmonary fibrosis, pulmonary arterial hypertension, 




Hypertension, peripheral edema, CHF, arterial ischemia, 
hypophosphatemia, gastrointestinal hemorrhage, neutropenia, 
leukopenia, thrombocytopenia, anemia, neutropenic fever, 
hemorrhage, ALT/AST increased, myalgia, peripheral neuropathy, 
pleural effusion, respiratory tract infection, sepsis 
BBW: Life-threatening blood clots and narrowing of blood vessels 
 
bosutinib 
Rash, decreased LVEF, CHF, QT prolongation, arterial thrombotic 
events, diarrhea/colitis, neutropenia, thrombocytopenia, 










anomalous result is explained by the existence of two types of TKI-resistance – Bcr-Abl- 
dependent, and Bcr-Abl independent. 
Bcr-Abl dependent resistance usually involves a point mutation(s) in the c-Abl 
portion of Bcr-Abl, specifically in the P-loop, C-helix, SH2 domain, substrate binding site, 
A-loop, or C-terminal lobe [50].  These mutations interfere with the binding of the TKI, 
leaving the tyrosine kinase in Bcr-Abl constitutively active [50].  Other mutations may 
prevent Bcr-Abl from entering its inactive conformation, thus precluding imatinib and 
nilotinib binding [50]. ‘Secondary resistance’ occurs when a patient initially responded to 
a TKI, but the drug has since become ineffective [64].  In these cases, patients are screened 
for common Bcr-Abl point mutations, and changed to a TKI that is effective against their 
specific mutation [64].  Ponatinib, the third generation TKI, is effective against most single 
point mutations, including the gatekeeper T315I [52]. However, even ponatinib is not 
universally effective against Bcr-Abl mutants, as it has decreased efficacy against the 
E255V and many T315-containing compound mutants, such as E255V/T315I [52, 61].   
Eleven percent of patients who fail TKI therapy have 2 or more mutations in the 
kinase domain, known as double mutants [52].  There are two types of double mutants – 
compound and polyclonal mutants [52]. In compound mutants, there are 2 separate 
mutations in one Bcr-Abl gene.  Patients with polyclonal mutations, on the other hand, 
have 2 different point mutations in 2 different Bcr-Abl genes, either in the same 
(duplication event) or different cells [52].    Of patients with double mutants, approximately 
70% are compound, and 30% are polyclonal [65]. Bcr-Abl duplication has also been 
correlated with TKI resistance and disease progression, and the duplication may lead to 
rapid Bcr-Abl mutation [66]. Further, multiple copies of Bcr-Abl are indicative of a poor 
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prognosis, even in the absence of mutations in the drug binding site [66]. 
If a TKI is ineffective despite the absence of point mutations, the patient is said to 
have ‘Bcr-Abl independent” resistance [67].  While this is a complicated and progressing 
area of research, a brief overview of the topic will give the reader the information needed 
for the remainder of this dissertation.  Bcr-Abl independent resistance has been associated 
with genetic variabilities in drug import and efflux [67-69], low trough drug concentrations 
[50], epigenetic modifications/upregulation of HDACs [50, 70],  growth factors in the bone 
marrow sustaining CML stem cells [51], and the activation of alternative signaling 
pathways [50].  Stat3 has recently been implemented as a key mediator of Bcr-Abl 
independent resistance, and the Deininger group has successfully screened and tested a 
Stat3 inhibitor + imatinib, a combination that is synthetically lethal to CML progenitor 
cells that display Bcr-Abl independent resistance [71, 72]. 
 
The Coiled-Coil 
 While TKIs target the kinase domain of the Abl portion of Bcr-Abl, the N-terminal 
coiled-coil domain is also of therapeutic interest. The coiled-coil (CC) located at the N-
terminus of Bcr-Abl acts as an oligomerization domain; specifically, a teteramer of Bcr-
Abl proteins is formed through a dimer of antiparallel dimers (Figure 1.3) [31].  Bcr-Abl 
proteins lacking this CC domain are unable to induce CML in murine models [73, 74].  A 
brief overview of CCs will give the reader the background needed for an understanding of 
the experimental works discussed in Chapters 3 and 4. 
Coiled-coils are a universal protein structure that commonly mediate protein homo- 






Figure 1.3 Bcr-Abl coiled-coil oligomerization.  A) The N-terminal coiled-coil of Bcr 
and Bcr-Abl consists of 2 α-helices; amino acids 5-15 make up the shorter helix 1, while 
helix 2 consists of residues 28-67. The coiled-coil can form an antiparallel homodimer (B) 
and subsequently a tetramer (C), via dimerization of dimers.  Diagrams were generated 





proteins [31], and it is estimated that 2-5% of all protein residues form CCs [75, 76].  CCs 
are characterized by 2-5 alpha helices that oligomerize to form a supercoil [31, 75].  The 
more common left-handed coiled coils generally contain a heptad repeat, HXXHCXC, with 
H being hydrophobic amino acids (isoleucine, leucine or valine most commonly), C being 
charged amino acids [31, 75]. Each heptad makes up two turns of the alpha helix, that is, 
there are 3.5 residues per turn [31, 77].  Coiled-coil oligomerization is driven by 
hydrophobic interactions, salt bridge formation, and helicity.  The hydrophobic residues 
thermodynamically drive the association of coiled-coils in aqueous environment, with the 
hydrophobic residues being buried at the interface of the two alpha helices [31, 75, 78].  
The charged residues increase complex stability by forming interhelical salt bridges [31]. 
 The CC of Bcr is a 72-amino acid sequence that encodes for two parallel alpha 
helixes connected by a short linker (Figure 1.3A) [79].  The shorter of the two, helix 1, is 
near the N-terminus of the protein, composed of aa 5-15.  Helix 1 and 2 are connected by 
a short, flexible linker that allows helix 2 to orient itself parallel to helix 1.  The longer 
helix 2 (aa 28-67) is the major dimerization interface.  While the two helices of one Bcr-
Abl molecule are oriented parallel, dimerization of two Bcr helix 2s is antiparallel (Figure 
1.3B).  Helix 1 can wrap around the backside of helix 2, participate in aromatic stacking, 
and thereby further stabilize the dimer [79].  The coiled coil can then proceed to form a 
tetramer from two CC dimers (Figure 1.3C). Studies have shown that the CC is required 
for the oncogenesis of Bcr-Abl; dimerization/tetramerization is a prerequisite to trans 
autophosphorylation [32].  
With this knowledge, the Ruthardt group set out to competitively interfere with 
Bcr-Abl dimerization by introducing excess copies of the CC into CML cells, with  
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marginal success [80, 81]. Dr. Andrew Dixon, a graduate from the Lim Lab, pioneered an 
improvement on this work in combination with Dr. Scott Pendley and Dr. Thomas 
Cheatham.  The antiparallel nature of the dimerization interface allowed for the rational 
design of a mimetic of Bcr CC that preferentially binds to the CC of Bcr-Abl (and Bcr) 
while avoiding homodimerization with itself [31].  Careful study of the dimerization 
interface led Dixon to propose the mutations of CC residues to create CCmut2, which 
preferentially bound to the wild-type CC (CCwt) of Bcr-Abl, while minimally 
autodimerizing [31].  The 5 mutations proposed by Dixon were C38A, S41R, L45D, E48R, 
and Q60E.  The mutations S41R and Q60E provides for 2 additional salt bridges between 
CCwt:CCmut3, L45D  and E48R destabilized the mutant homodimer, and C38A was 
incorporated for crystallographic concerns [31].   
This hypothesis was born out by computational modelling in the Cheatham group, 
and supported by in vitro work, performed by transfecting a gene encoding for CCmut2 [31].  
CCmut2 reduced the transformative ability and induced apoptosis of Bcr-Abl+ (but not 
negative) cells, and decreased phosphorylation of Bcr-Abl and downstream targets Stat5 
and CrkL [31]. An additional mutation, K39E, was proposed to decrease homodimerization 
of the mutant CC by creating an additional charge-charge repulsion with E60 of the mutant 
CC, but not the Q60 in CCwt (Figure 1.4A).  While decreased homodimerization was 
supported by in silico modeling and a mammalian two-hybrid assay (1.4b), the new CCmut3 
was not statistically superior in biologic assays [82].  However, subsequent work utilized 







Figure 1.4: CCmut3 dimerization with CCwt. A) Helical wheel diagram displaying 
interactions between CCmut3:CCwt(left) and CCmut3:CCmut3 (right).  Above and below the 
helical wheels are individual residues from each domain.  Side chains of those residues are 
color-coded as follows: blue = basic, red = acidic, yellow = serine.  Potential ionic 
interactions are shown with the dotted lines, whereas potential charge-charge repulsions 
are shown with a solid line.  B) A mammalian two-hybrid assay suggests CCmut3 is a 






Statement of Objectives 
The shortcomings of currently approved (and future) TKIs necessitate the 
development of CML therapeutics that target domains other than the tyrosine kinase.  The 
original design and optimization of our oligomerization inhibitor (CCmut3) has been 
performed. The overall goal of the work in the following studies is to translate the successes 
seen with gene delivery of CCmut into a clinically-relevant protein therapeutic for CML.  
Towards this goal, we cloned and purified CCmut3 protein with an N-terminal cell-
penetrating peptide. This improved the cell permeability and selective delivery of CCmut3 
to leukemic cells.   
The protein we have designed is specific to Bcr-Abl; we expect minimal off-target 
effects.  Further, the dimerization interface has many more contacts than do TKIs with the 
TK pocket in Bcr-Abl.  Therefore, we believe resistance to CCmut would be less likely 
than what is seen with TKIs.  Further, as we are targeting a dimerization interface, it is 
likely that any mutations in the CC of Bcr-Abl that abrogated CCmut binding would also 
likely prevent Bcr-Abl CC:CC dimerization, resulting in ‘auto-inactivation’ of Bcr-Abl.  
This strategy could therefore result in a therapeutic with greater long-term efficacy and 




Research Aim 1 
 
CCmut3 was previously delivered via gene delivery, which is not practical for the 
clinical treatment of CML.  Therefore, a CCmut3 protein will be purified.  An N-terminal 
cell-penetrating peptide will be included to improve cell penetration.  
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Research Aim 2 
Delivery of the protein CCmut3  to leukemia cells will be accomplished by the use 
of a leukemia-specific cell-penetrating peptide (LS-CPP).  Further LS-CPP-CCmut3 will 
induce apoptosis in Bcr-Abl+ cell lines, while being nontoxic to Bcr-Abl- leukemia cell 
lines. 
Research Aim 3 
 In vivo proteolysis of CPP-CCmut3 will limit translatability to the clinic.  To remedy 
this, peptide stapling is implemented to improve the protease resistance of CCmut3.  We aim 
to see if these staples do indeed increase the protease stability of our CCmut3 constructs. 
 
Research Aim 4 
Stapling of hydrophilic proteins may cause protein misfolding.  Future work will 



















[1] O.O. Olabisi, G.M. Mahon, E.V. Kostenko, Z. Liu, H.L. Ozer, I.P. Whitehead, Bcr 
interacts with components of the endosomal sorting complex required for transport-
I and is required for epidermal growth factor receptor turnover, Cancer Res 66(12) 
(2006) 6250-7.   
 
[2] R. Ren, Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous 
leukaemia, Nat Rev Cancer 5(3) (2005) 172-83. 
 
[3] E. Laurent, M. Talpaz, H. Kantarjian, R. Kurzrock, The BCR gene and philadelphia 
chromosome-positive leukemogenesis, Cancer Res 61(6) (2001) 2343-55. 
 
[4] J.D. Alexis, N. Wang, W. Che, N. Lerner-Marmarosh, A. Sahni, V.A. Korshunov, 
Y. Zou, B. Ding, C. Yan, B.C. Berk, J. Abe, Bcr kinase activation by angiotensin 
II inhibits peroxisome-proliferator-activated receptor gamma transcriptional 
activity in vascular smooth muscle cells, Circ Res 104(1) (2009) 69-78. 
 
[5] T. Kato, Molecular genetics of bipolar disorder and depression, Psychiatry Clin 
Neurosci 61(1) (2007) 3-19. 
 
[6] A.R. Park, D. Oh, S.H. Lim, J. Choi, J. Moon, D.Y. Yu, S.G. Park, N. Heisterkamp, 
E. Kim, P.K. Myung, J.R. Lee, Regulation of dendritic arborization by BCR Rac1 
GTPase-activating protein, a substrate of PTPRT, J Cell Sci 125(Pt 19) (2012) 
4518-31. 
 
[7] A.S. Narayanan, S.B. Reyes, K. Um, J.H. McCarty, K.F. Tolias, The Rac-GAP Bcr 
is a novel regulator of the Par complex that controls cell polarity, Mol Biol Cell 
24(24) (2013) 3857-68. 
 
[8] D. Diekmann, S. Brill, M.D. Garrett, N. Totty, J. Hsuan, C. Monfries, C. Hall, L. 
Lim, A. Hall, Bcr encodes a GTPase-activating protein for p21rac, Nature 
351(6325) (1991) 400-2. 
 
[9] S.M. Kweon, Y.J. Cho, P. Minoo, J. Groffen, N. Heisterkamp, Activity of the Bcr 
GTPase-activating domain is regulated through direct protein/protein interaction 
with the Rho guanine nucleotide dissociation inhibitor, J Biol Chem 283(6) (2008) 
3023-30. 
 
[10] M.W. Deininger, B.J. Druker, Specific targeted therapy of chronic myelogenous 
leukemia with imatinib, Pharmacol Rev 55(3) (2003) 401-23. 
 
[11] M. Preyer, P. Vigneri, J.Y. Wang, Interplay between kinase domain 
autophosphorylation and F-actin binding domain in regulating imatinib sensitivity 




[12] Y. Maru, O.N. Witte, The BCR gene encodes a novel serine/threonine kinase 
activity within a single exon, Cell 67(3) (1991) 459-68. 
 
[13] H. Modi, L. Li, S. Chu, J. Rossi, J.K. Yee, R. Bhatia, Inhibition of Grb2 expression 
demonstrates an important role in BCR-ABL-mediated MAPK activation and 
transformation of primary human hematopoietic cells, Leukemia 25(2) (2011) 305-
12. 
 
[14] J.W. Voncken, H. van Schaick, V. Kaartinen, K. Deemer, T. Coates, B. Landing, 
P. Pattengale, O. Dorseuil, G.M. Bokoch, J. Groffen, et al., Increased neutrophil 
respiratory burst in bcr-null mutants, Cell 80(5) (1995) 719-28. 
 
[15] Y.J. Cho, J.M. Cunnick, S.J. Yi, V. Kaartinen, J. Groffen, N. Heisterkamp, Abr and 
Bcr, two homologous Rac GTPase-activating proteins, control multiple cellular 
functions of murine macrophages, Mol Cell Biol 27(3) (2007) 899-911. 
 
[16] B. Nagar, O. Hantschel, M.A. Young, K. Scheffzek, D. Veach, W. Bornmann, B. 
Clarkson, G. Superti-Furga, J. Kuriyan, Structural basis for the autoinhibition of c-
Abl tyrosine kinase, Cell 112(6) (2003) 859-71. 
 
[17] S.E. Hernandez, M. Krishnaswami, A.L. Miller, A.J. Koleske, How do Abl family 
kinases regulate cell shape and movement?, Trends Cell Biol 14(1) (2004) 36-44. 
 
[18] A. Sirvent, C. Benistant, S. Roche, Cytoplasmic signalling by the c-Abl tyrosine 
kinase in normal and cancer cells, Biol Cell 100(11) (2008) 617-31. 
 
[19] O. Hantschel, B. Nagar, S. Guettler, J. Kretzschmar, K. Dorey, J. Kuriyan, G. 
Superti-Furga, A myristoyl/phosphotyrosine switch regulates c-Abl, Cell 112(6) 
(2003) 845-57. 
 
[20] J.Y. Wang, Regulation of cell death by the Abl tyrosine kinase, Oncogene 19(49) 
(2000) 5643-50. 
 
[21] X. Wang, L. Zeng, J. Wang, J.F. Chau, K.P. Lai, D. Jia, A. Poonepalli, M.P. Hande, 
H. Liu, G. He, L. He, B. Li, A positive role for c-Abl in Atm and Atr activation in 
DNA damage response, Cell Death Differ 18(1) (2011) 5-15. 
 
[22] C.E. Canman, D.S. Lim, K.A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. 
Appella, M.B. Kastan, J.D. Siliciano, Activation of the ATM kinase by ionizing 
radiation and phosphorylation of p53, Science 281(5383) (1998) 1677-9. 
 
[23] M. Kurokawa, S. Kornbluth, Caspases and kinases in a death grip, Cell 138(5) 
(2009) 838-54. 
 
[24] M.H. David-Cordonnier, M. Hamdane, C. Bailly, J.C. D'Halluin, The DNA binding 
domain of the human c-Abl tyrosine kinase preferentially binds to DNA sequences 
28 
 
containing an AAC motif and to distorted DNA structures, Biochemistry 37(17) 
(1998) 6065-76. 
 
[25] S. Wong, O.N. Witte, The BCR-ABL story: bench to bedside and back, Annu Rev 
Immunol 22 (2004) 247-306. 
 
[26] R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter, Glivec (STI571, 
imatinib), a rationally developed, targeted anticancer drug, Nat Rev Drug Discov 
1(7) (2002) 493-502. 
 
[27] N. Heisterkamp, G. Jenster, J. ten Hoeve, D. Zovich, P.K. Pattengale, J. Groffen, 
Acute leukaemia in bcr/abl transgenic mice, Nature 344(6263) (1990) 251-3. 
 
[28] G.Q. Daley, R.A. Van Etten, D. Baltimore, Induction of chronic myelogenous 
leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science 
247(4944) (1990) 824-30. 
 
[29] L.A. Hazlehurst, N.N. Bewry, R.R. Nair, J. Pinilla-Ibarz, Signaling networks 
associated with BCR-ABL-dependent transformation, Cancer Control 16(2) (2009) 
100-7. 
 
[30] D. Miroshnychenko, A. Dubrovska, S. Maliuta, G. Telegeev, P. Aspenstrom, Novel 
role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-
protein and protein-lipid interactions, Exp Cell Res 316(4) (2010) 530-42. 
 
[31] A.S. Dixon, S.S. Pendley, B.J. Bruno, D.W. Woessner, A.A. Shimpi, T.E. 
Cheatham, 3rd, C.S. Lim, Disruption of Bcr-Abl coiled coil oligomerization by 
design, J Biol Chem 286(31) (2011) 27751-60. 
 
[32] J.R. McWhirter, D.L. Galasso, J.Y. Wang, A coiled-coil oligomerization domain 
of Bcr is essential for the transforming function of Bcr-Abl oncoproteins, Mol Cell 
Biol 13(12) (1993) 7587-95. 
 
[33] J. Liu, M. Campbell, J.Q. Guo, D. Lu, Y.M. Xian, B.S. Andersson, R.B. Arlinghaus, 
BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 
BCR on tyrosine predominantly within the first BCR exon, Oncogene 8(1) (1993) 
101-9. 
 
[34] H. Pluk, K. Dorey, G. Superti-Furga, Autoinhibition of c-Abl, Cell 108(2) (2002) 
247-59. 
 
[35] A.M. Pendergast, L.A. Quilliam, L.D. Cripe, C.H. Bassing, Z. Dai, N. Li, A. Batzer, 
K.M. Rabun, C.J. Der, J. Schlessinger, et al., BCR-ABL-induced oncogenesis is 
mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein, 




[36] T. O'Hare, M.W. Deininger, C.A. Eide, T. Clackson, B.J. Druker, Targeting the 
BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-
positive leukemia, Clin Cancer Res 17(2) (2011) 212-21. 
 
[37] D. Cortez, L. Kadlec, A.M. Pendergast, Structural and signaling requirements for 
BCR-ABL-mediated transformation and inhibition of apoptosis, Mol Cell Biol 
15(10) (1995) 5531-41. 
 
[38] J.E. Cortes, M. Talpaz, S. O'Brien, S. Faderl, G. Garcia-Manero, A. Ferrajoli, S. 
Verstovsek, M.B. Rios, J. Shan, H.M. Kantarjian, Staging of chronic myeloid 
leukemia in the imatinib era: an evaluation of the World Health Organization 
proposal, Cancer 106(6) (2006) 1306-15. 
 
[39] D.G. Savage, R.M. Szydlo, J.M. Goldman, Clinical features at diagnosis in 430 
patients with chronic myeloid leukaemia seen at a referral centre over a 16-year 
period, Br J Haematol 96(1) (1997) 111-6. 
 
[40] U. Bacher, W. Kern, S. Schnittger, W. Hiddemann, C. Schoch, T. Haferlach, Blast 
count and cytogenetics correlate and are useful parameters for the evaluation of 
different phases in chronic myeloid leukemia, Leuk Lymphoma 46(3) (2005) 357-
66. 
 
[41] C.J. Sherr, F. McCormick, The RB and p53 pathways in cancer, Cancer Cell 2(2) 
(2002) 103-12. 
 
[42] B. Calabretta, D. Perrotti, The biology of CML blast crisis, Blood 103(11) (2004) 
4010-22. 
 
[43] N. Howlander, N. Krapcho, M. Miller, D. Bishop, K. Altekruse, S. Kosary, C. Yu, 
M. Ruhl, J. Tatalovich, Z. Mariotto, A. Lewis, D. Chen, H. Feuer, E. Cronin. SEER 
Cancer Statistics, 2015. Online. 2016 July. Availble from URL: 
http://seer.cancer.gov/statfacts/html/cmyl.html. 
 
[44] R.W. Bolin, W.A. Robinson, J. Sutherland, R.F. Hamman, Busulfan versus 
hydroxyurea in long-term therapy of chronic myelogenous leukemia, Cancer 50(9) 
(1982) 1683-6. 
 
[45] R. Hehlmann, H. Heimpel, J. Hasford, H.J. Kolb, H. Pralle, D.K. Hossfeld, W. 
Queisser, H. Loffler, A. Hochhaus, B. Heinze, et al., Randomized comparison of 
interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. 
The German CML Study Group, Blood 84(12) (1994) 4064-77. 
 
[46] J.F. Zeidner, M. Zahurak, G.L. Rosner, C.D. Gocke, R.J. Jones, B.D. Smith, The 
evolution of treatment strategies for patients with chronic myeloid leukemia 
relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors 
replace donor lymphocyte infusions?, Leuk Lymphoma 56(1) (2015) 128-34. 
30 
 
[47] M. Talpaz, J. Mercer, R. Hehlmann, The interferon-alpha revival in CML, Ann 
Hematol 94 Suppl 2 (2015) S195-207. 
 
[48] A.M. Cornelison, M.A. Welch, C. Koller, E. Jabbour, Dasatinib combined with 
interferon-alfa induces a complete cytogenetic response and major molecular 
response in a patient with chronic myelogenous leukemia harboring the T315I 
BCR-ABL1 mutation, Clin Lymphoma Myeloma Leuk 11 Suppl 1 (2011) S111-3. 
 
[49] J. Cortes, J.H. Lipton, D. Rea, R. Digumarti, C. Chuah, N. Nanda, A.C. Benichou, 
A.R. Craig, M. Michallet, F.E. Nicolini, H. Kantarjian, Phase 2 study of 
subcutaneous omacetaxine mepesuccinate after TKI failure in patients with 
chronic-phase CML with T315I mutation, Blood 120(13) (2012) 2573-80. 
 
[50] D. Bixby, M. Talpaz, Mechanisms of resistance to tyrosine kinase inhibitors in 
chronic myeloid leukemia and recent therapeutic strategies to overcome resistance, 
Hematology Am Soc Hematol Educ Program  (2009) 461-76. 
 
[51] K. Yang, L.W. Fu, Mechanisms of resistance to BCR-ABL TKIs and the 
therapeutic strategies: A review, Crit Rev Oncol Hematol 93(3) (2015) 277-92. 
 
[52] G.D. Miller, B.J. Bruno, C.S. Lim, Resistant mutations in CML and Ph(+)ALL - 
role of ponatinib, Biologics 8 (2014) 243-54. 
 
[53] D.W. Woessner, C.S. Lim, M.W. Deininger, Development of an effective therapy 
for chronic myelogenous leukemia, Cancer J 17(6) (2011) 477-86. 
 
[54] A.A. Mian, M. Schull, Z. Zhao, C. Oancea, A. Hundertmark, T. Beissert, O.G. 
Ottmann, M. Ruthardt, The gatekeeper mutation T315I confers resistance against 
small molecules by increasing or restoring the ABL-kinase activity accompanied 
by aberrant transphosphorylation of endogenous BCR, even in loss-of-function 
mutants of BCR/ABL, Leukemia 23(9) (2009) 1614-21. 
 
[55] T. O'Hare, M.S. Zabriskie, A.M. Eiring, M.W. Deininger, Pushing the limits of 
targeted therapy in chronic myeloid leukaemia, Nat Rev Cancer 12(8) (2012) 513-
26. 
 
[56] M. Azam, G.Q. Daley, Anticipating clinical resistance to target-directed agents : 
the BCR-ABL paradigm, Mol Diagn Ther 10(2) (2006) 67-76. 
 
[57] S. Redaelli, R. Piazza, R. Rostagno, V. Magistroni, P. Perini, M. Marega, C. 
Gambacorti-Passerini, F. Boschelli, Activity of bosutinib, dasatinib, and nilotinib 
against 18 imatinib-resistant BCR/ABL mutants, J Clin Oncol 27(3) (2009) 469-
71. 
 
[58] M. Baccarani, Managing children with chronic myeloid leukaemia, Br J Haematol 
169(5) (2015) 759-60. 
31 
 
[59] E.a.K. Jabbour, H., How we treat patients with chronic myeloid leukemia, 
Oncology Times 38(4) (2016) 8-9. 
 
[60] S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, 
J.J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J.L. Nielsen, P. 
Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. 
Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A.E. Bolton, R. Capdeville, B.J. 
Druker, Imatinib compared with interferon and low-dose cytarabine for newly 
diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med 348(11) (2003) 
994-1004. 
 
[61] M.S. Zabriskie, C.A. Eide, S.K. Tantravahi, N.A. Vellore, J. Estrada, F.E. Nicolini, 
H.J. Khoury, R.A. Larson, M. Konopleva, J.E. Cortes, H. Kantarjian, E.J. Jabbour, 
S.M. Kornblau, J.H. Lipton, D. Rea, L. Stenke, G. Barbany, T. Lange, J.C. 
Hernandez-Boluda, G.J. Ossenkoppele, R.D. Press, C. Chuah, S.L. Goldberg, M. 
Wetzler, F.X. Mahon, G. Etienne, M. Baccarani, S. Soverini, G. Rosti, P. Rousselot, 
R. Friedman, M. Deininger, K.R. Reynolds, W.L. Heaton, A.M. Eiring, A.D. 
Pomicter, J.S. Khorashad, T.W. Kelley, R. Baron, B.J. Druker, M.W. Deininger, T. 
O'Hare, BCR-ABL1 compound mutations combining key kinase domain positions 
confer clinical resistance to ponatinib in Ph chromosome-positive leukemia, Cancer 
Cell 26(3) (2014) 428-42. 
 
[62] A. Wylie, J. Schoepfer, G. Berellini, H. Cai, G. Caravatti, S. Cotesta, S. Dodd, J. 
Donovan, B. Erb, P. Furet, G. Gangal, R. Grotzfeld, Q. Hassan, T. Hood, V. Iyer, 
S. Jacob, W. Jahnke, F. Lombardo, A. Loo, P.W. Manley, A. Marzinzik, M. Palmer, 
X. Pelle, B. Salem, S. Sharma, S. Thohan, S. Zhu, N. Keen, L. Petruzzelli, K.G. 
Vanasse, W.R. Sellers, ABL001, a potent allosteric inhibitor of BCR-ABL, 
prevents emergence of resistant disease when administered in combination with 
nilotinib in an in vivo murine model of chronic myeloid leukemia, Blood 124(21) 
(2014) 398. 
 
[63] P.K. Bhamidipati, H. Kantarjian, J. Cortes, A.M. Cornelison, E. Jabbour, 
Management of imatinib-resistant patients with chronic myeloid leukemia, Ther 
Adv Hematol 4(2) (2013) 103-17. 
 
[64] M. Baccarani, J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, F. 
Cervantes, M. Deininger, A. Gratwohl, F. Guilhot, A. Hochhaus, M. Horowitz, T. 
Hughes, H. Kantarjian, R. Larson, J. Radich, B. Simonsson, R.T. Silver, J. 
Goldman, R. Hehlmann, Chronic myeloid leukemia: an update of concepts and 
management recommendations of European LeukemiaNet, J Clin Oncol 27(35) 
(2009) 6041-51. 
 
[65] J.S. Khorashad, T.W. Kelley, P. Szankasi, C.C. Mason, S. Soverini, L.T. Adrian, 
C.A. Eide, M.S. Zabriskie, T. Lange, J.C. Estrada, A.D. Pomicter, A.M. Eiring, I.L. 
Kraft, D.J. Anderson, Z. Gu, M. Alikian, A.G. Reid, L. Foroni, D. Marin, B.J. 
Druker, T. O'Hare, M.W. Deininger, BCR-ABL1 compound mutations in tyrosine 
32 
 
kinase inhibitor-resistant CML: frequency and clonal relationships, Blood 121(3) 
(2013) 489-98. 
 
[66] W. Al-Achkar, A. Wafa, F. Moassass, E. Klein, T. Liehr, Multiple copies of BCR-
ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib 
mesylate-resistant chronic myeloid leukemia patient, Oncol Lett 5(5) (2013) 1579-
1582. 
 
[67] S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, 
M. Krajinovic, F.X. Mahon, Multidrug resistance gene (MDR1) polymorphisms 
are associated with major molecular responses to standard-dose imatinib in chronic 
myeloid leukemia, Blood 112(5) (2008) 2024-7. 
 
[68] L.C. Crossman, B.J. Druker, M.W. Deininger, M. Pirmohamed, L. Wang, R.E. 
Clark, hOCT 1 and resistance to imatinib, Blood 106(3) (2005) 1133-4; author reply 
1134. 
 
[69] L. Wang, A. Giannoudis, S. Lane, P. Williamson, M. Pirmohamed, R.E. Clark, 
Expression of the uptake drug transporter hOCT1 is an important clinical 
determinant of the response to imatinib in chronic myeloid leukemia, Clin 
Pharmacol Ther 83(2) (2008) 258-64. 
 
[70] W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. 
Rocha, J. Wu, F. Giles, P.W. Manley, P. Atadja, K. Bhalla, Combined effects of 
novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 
against Bcr-Abl-expressing human leukemia cells, Blood 108(2) (2006) 645-52. 
 
[71] A.M. Eiring, B.D. Page, I.L. Kraft, C.C. Mason, N.A. Vellore, D. Resetca, M.S. 
Zabriskie, T.Y. Zhang, J.S. Khorashad, A.J. Engar, K.R. Reynolds, D.J. Anderson, 
A. Senina, A.D. Pomicter, C.C. Arpin, S. Ahmad, W.L. Heaton, S.K. Tantravahi, 
A. Todic, R. Colaguori, R. Moriggl, D.J. Wilson, R. Baron, T. O'Hare, P.T. 
Gunning, M.W. Deininger, Combined STAT3 and BCR-ABL1 inhibition induces 
synthetic lethality in therapy-resistant chronic myeloid leukemia, Leukemia 29(3) 
(2015) 586-97. 
 
[72] A.M. Eiring, I.L. Kraft, B.D. Page, T. O'Hare, P.T. Gunning, M.W. Deininger, 
STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid 
leukemia, Leukemia supplements 3(Suppl 1) (2014) S5-6. 
 
[73] X. Zhang, R. Subrahmanyam, R. Wong, A.W. Gross, R. Ren, The NH(2)-terminal 
coiled-coil domain and tyrosine 177 play important roles in induction of a 
myeloproliferative disease in mice by Bcr-Abl, Mol Cell Biol 21(3) (2001) 840-53. 
 
[74] Y. He, J.A. Wertheim, L. Xu, J.P. Miller, F.G. Karnell, J.K. Choi, R. Ren, W.S. 
Pear, The coiled-coil domain and Tyr177 of bcr are required to induce a murine 
33 
 
chronic myelogenous leukemia-like disease by bcr/abl, Blood 99(8) (2002) 2957-
68. 
 
[75] P. Burkhard, J. Stetefeld, S.V. Strelkov, Coiled coils: a highly versatile protein 
folding motif, Trends Cell Biol 11(2) (2001) 82-8. 
 
[76] E. Wolf, P.S. Kim, B. Berger, MultiCoil: a program for predicting two- and three-
stranded coiled coils, Protein Sci 6(6) (1997) 1179-89. 
 
[77] A. Lupas, Coiled coils: new structures and new functions, Trends Biochem Sci 
21(10) (1996) 375-82. 
 
[78] D.N. Woolfson, The design of coiled-coil structures and assemblies, Adv Protein 
Chem 70 (2005) 79-112. 
 
[79] X. Zhao, S. Ghaffari, H. Lodish, V.N. Malashkevich, P.S. Kim, Structure of the 
Bcr-Abl oncoprotein oligomerization domain, Nat Struct Biol 9(2) (2002) 117-20. 
 
[80] T. Beissert, A. Hundertmark, V. Kaburova, L. Travaglini, A.A. Mian, C. Nervi, M. 
Ruthardt, Targeting of the N-terminal coiled coil oligomerization interface by a 
helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL, Int J Cancer 
122(12) (2008) 2744-52. 
 
[81] T. Beissert, E. Puccetti, A. Bianchini, S. Guller, S. Boehrer, D. Hoelzer, O.G. 
Ottmann, C. Nervi, M. Ruthardt, Targeting of the N-terminal coiled coil 
oligomerization interface of BCR interferes with the transformation potential of 
BCR-ABL and increases sensitivity to STI571, Blood 102(8) (2003) 2985-93. 
 
[82] A.S. Dixon, G.D. Miller, B.J. Bruno, J.E. Constance, D.W. Woessner, T.P. Fidler, 
J.C. Robertson, T.E. Cheatham, 3rd, C.S. Lim, Improved coiled-coil design 





Reprinted with permission from Molecular Pharmaceutics 2013; 4(11):1443-67. Benjamin 






BASICS AND RECENT ADVANCES IN PEPTIDE  
AND PROTEIN DRUG DELIVERY 
 
Abstract 
While the peptide and protein therapeutic market has developed significantly in the 
past decades, delivery has limited their use.  While oral delivery is preferred, most are 
currently delivered intravenously or subcutaneously due to degradation and limited 
absorption in the GI tract.  Therefore, absorption enhancers, enzyme inhibitors, carrier 
systems, and stability enhancers are being studied to facilitate oral peptide delivery.  
Additionally, transdermal peptide delivery avoids the issues of the GI tract, but also faces 
absorption limitations.   Due to proteases, opsonization, and agglutination, free peptides 
are not systemically stable without modifications.  This review discusses oral and 
transdermal peptide drug delivery, focusing on barriers and solutions to absorption and 




Peptides and proteins have great potential as therapeutics.  Currently, the market 
for peptide and protein drugs is estimated to be greater than $40 billion/year, or 10% of the 
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pharmaceutical market [1].  This market is growing much faster than that of small 
molecules, and will make up an even larger proportion of the market in the future [1].  At 
present there over 100 approved peptide-based therapeutics on the market, with the 
majority being smaller than 20 amino acids [1].  Compared to the typical small molecule 
drugs which currently make up the majority of the pharmaceutical market, peptides and 
proteins can be highly selective as they have multiple points of contact with their targets 
[1].  Increased selectivity may also result in decreased side effects and toxicity.  Peptides 
can be designed to target a broad range of molecules, giving them almost limitless 
possibilities in fields such as oncology, immunology, infectious disease, and 
endocrinology. For an overview of some popular therapeutic peptides/proteins, see Table 
2.1. 
These peptide and protein therapeutics have disadvantages as well such as low 
bioavailability and metabolic labiality.   Oral bioavailability of peptides is limited by 
degradation in the GI tract as well as their inability to cross the epithelial barrier.  These 
therapeutics tend to have high molecular weights, low lipophilicity, and charged functional 
groups which hamper their absorption [2].   These characteristics lead to the low 
bioavailability of most orally administered peptides (<2%) and short half-lives (<30 
minutes) [3].  Intravenous (IV) or subcutaneous (SubQ) delivery of these therapeutics 
overcomes the issue of absorption, but other factors limit the bioavailability of peptide and 
protein therapeutics: systemic proteases, rapid metabolism, opsonization, conformational  
changes, dissociation of subunit proteins, noncovalent complexation with blood products, 
and destruction of labile side-groups [1, 4]. 







Table 2.1. Overview of a selection of currently available peptide/protein therapeutics.   
RA: Rheumatoid Arthritis; AA: Amino acids; D-AA: D-amino acids; DM: Diabetes 
Mellitus; GLP-1: Glucagon-like peptide 1; SubQ: Subcutaneous 
 



















































LIRAGLUTIDE  31 AA, 
3.8 kDa 
Type 2 DM 
(GLP-1 agonist) 




BIVALIRUDIN 2.2 kDa Anticoagulant $481 Million 
(2011) [11] 
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development of systems which allow for the oral delivery of peptide and protein 
therapeutics [13].  This review will summarize the barriers to various noninvasive delivery 
methods with a focus on oral and transdermal delivery. Additionally, current methods to 
overcome these delivery barriers will be discussed.  The final portion of this paper will 





Barriers to Oral Delivery 
 
Oral delivery is the preferred route of drug administration, as the majority of 
patients see it as the most convenient way to take their drugs[14].  Drugs taken by the oral 
route have the highest level of patient compliance due to the ease and simplicity of taking 
medications [14, 15].  Despite the large number of protein therapeutics being discovered 
each year, oral delivery continues to be a barrier.  As a whole, protein and peptide drugs 
have low bioavailability when administered orally due to problematic barriers including 
gastrointestinal proteases, the epithelial barrier, and efflux pumps.  Common routes of 
administration for the systemic delivery of peptide and protein therapeutics are summarized 
in Figure 2.1.  Table 2.2 provides an overview of the delivery enhancers discussed in this 
paper with regard to where they act. 
Proteins are degraded via enzymes and hydrolysis in the acidic environment in the 
stomach and  in the GI tract by a number of proteases and peptidases  [16-18].  The human 
degradome, a complete list of proteases in human cells, consists of at least 569 proteases 








Figure 2.1.  Routes of administration for systemic delivery of peptides and proteins.  


















Table 2.2 Overview of peptide modifications and delivery systems. CPP: Cell-












and metalloproteinases [20].  These proteases play roles in DNA replication, transcription, 
cell proliferation, fertility, stem cell mobilization, hemostasis, inflammation, senescence, 
apoptosis, and many other vital cellular and regulatory processes [20].  Trypsin, 
carboxypeptidase, and chymotrypsin are secreted from the pancreas into the small intestine, 
mostly in the duodenum, where they are present in gram quantities.  These enzymes are 
responsible for 20% of the enzymatic degradation of ingested proteins and peptides [16, 
21, 22].  The causes of the remaining 80% of enzymatic degradation are discussed below. 
While peptide degradation is one obstacle to oral protein therapeutic delivery, the 
epithelial barrier of the small intestine poses an even greater challenge.  This barrier 
consists of a single layer of columnar epithelial cells supported by lamina propria and 
muscularis mucosa [21].  Molecules can cross the epithelium by either transcellular or 
paracellular routes as depicted in Figure 2.2.  Apical to the epithelial cell barrier is the 
mucosal layer, which contains glycocalyx, a layer of sulfated mucopolysaccharides [21], 
glycoproteins, enzymes, electrolytes, and water [21, 23].  Additionally, most mucosal 
surfaces are coated by a hydrated gel consisting of mucins, which are high molecular 
weight, heavily glycosylated proteins [24]. Bulk flow to the epithelial cells is limited, 
creating an unstirred layer near the epithelial surface [24].  This unstirred layer is protected 
from convective mixing forces, slowing the absorption of small molecules and ions.  Once 
a molecule passes the mucosal layer, however, the unstirred layer may act as an absorption 
enhancer by allowing the particle more time exposed to the epithelial barrier [24]. 
The brush border membrane (Figure 2.2) is where the majority of peptide 
degradation occurs [21].  The brush border is the microvilli-covered surface of cells found 







Figure 2.2.  Intestinal barriers to peptide delivery. Epithelial intestinal barrier is made 
up of a single layer of columnar epithelial cells.  The apical side of the barrier contains the 
mucosal layer. Drugs may penetrate the epithelial barrier either through the transcellular 













absorption [3].  Tight junctions (TJs) mediate the paracellular pathway of absorption in 
intact membranes (Figure 2.2) [24].  TJs are the rate limiting step in transepithelial 
transport [24].  Adherin junctions, which are required for the assembly of TJs, are a multi-
protein complex made of transmembrane proteins, peripheral membrane proteins, and 
regulatory molecules including kinases [24].  Adherin junctions work with desmosomes to 
provide the adhesive bonds that maintain cellular proximity and intercellular 
communication [24].  Both adherin junctions and TJs are supported by dense perijunctional 
rings of actin and myocin.  The most important proteins to tight junction assembly and 
maintenance are zonula occludens 1 and 2 along with transmembrane proteins in the 
claudin family [24, 25]. 
A final barrier to protein drug absorption is efflux pumps, depicted in Figure 2.2.  
These are proteins belonging to the ATP binding cassette (ABC) superfamily which sit on 
the apical side of mature epithelial cells and mediate  multidrug resistance (MDR) in 
humans [26].  Forty-nine ABC proteins have been Identified, many of which are 
overexpressed in MDR cell lines [27].  One specific example of an efflux pump is P-
glycoprotein-I, or PGP-I (also known as MDR1) [28].  After peptides are absorbed in the 
GI, PGP-I can pump the drug or peptide back into the GI lumen [16].  It is known that 
linear lipophilic and cyclic peptides (including cyclosporine) are substrates of PGP-I [16, 
29]. 
Even after the drug is absorbed, first-pass metabolism can greatly reduce the 
fraction of drug which reaches systemic circulation.  The first-pass effect, as it is known, 
is the phenomenon which accounts for the decreased fraction of drug systemically available 
compared to the fraction of drug that is absorbed.  Once a drug is absorbed after oral 
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administration it enters the hepatic portal system.  It is then carried via the portal vein to 
the liver prior to reaching the rest of the body.  The liver then metabolizes the drug, 
reducing the amount of the active, parent compound which enters systemic circulation [30].  
Intravenous (IV), intramuscular (IM), subcutaneous (SubQ), sublingual (SL), intrarectal, 
transdermal, and pulmonary routes of administration avoid or minimize the first-pass effect 
[31]. 
While these barriers to absorption are large, much work has been done in order to 
overcome them.  Methods to improve the bioavailability of protein therapeutics can be 
broadly classified into the following categories: structural modifications, enzyme 
inhibitors, absorption enhancers, and carrier systems. 
 
Strategies for Oral Delivery of Peptides 
 
Direct Structural Modification 
 
One class of structural modifications under study is cyclization.  The benefits of 
cyclization to oral peptide/protein therapy are evidenced by cyclosporine (CSA).   CSA is 
a fungal-derived, nonribosomal 11-amino acid peptide with a cyclic backbone and a single 
D-amino acid [1].  While most naturally occurring proteins and peptides are composed of 
L-amino acids,  D-amino acids are found in some naturally occurring nonribosomally 
synthesized peptides [32].  Cyclosporine is used most frequently as an immune system 
modulator for the prevention of solid organ rejection [33].  This cyclic peptide is resistant 
to proteolytic degradation and also has higher than expected absorption after oral 
administration [1].  The superior oral bioavailability is thought to be due to a number of 
properties including decreased flexibility and hydrogen bonding characteristics. The cyclic 
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nature of CSA incorporates 7 n-methyl groups that reduce the number of hydrogen bond 
donors, and the remaining 4 hydrogens bond intramolecularly .  This reduction in 
intermolecular bonding reduces hydrophilicity.   CSA has lipophilic side chain amino acids 
which further raise its lipophilicity and allow it to cross the gut wall [1].  Other peptides 
such as somatostatin and encephalin have shown similar characteristics and improved oral 
absorption after cyclization [34, 35].  Generically, cyclization is usually carried out 
between side chains or ends of the peptide sequences through disulfide bonds, lanthionine, 
dicarba, hydrazine, or lactam bridges [1].  While cyclization is an option for some peptides, 
its widespread use is limited when larger peptides and proteins are needed for therapy.   
PEGylation is a modification option for some peptides not amenable to cyclization.  
Polyethylene glycol, or PEG, is an amphipathic molecule that dissolves in organic solvents 
as well as in water [36].  Both PEG and its metabolites are nontoxic and US-FDA approved 
[37, 38].  PEG has been shown to be toxic at high parenteral doses, much higher than the 
amount of PEG a patient would be exposed to with current PEGylated therapies [39].  If 
PEG toxicity is seen it usually presents in the kidney, as unmodified PEG is mainly cleared 
through the kidneys.  Interesting, even when pathological changes were seen, no functional 
deficits resulted [39]. Case studies exist which demonstrate high doses of PEG can induce 
acute tubular necrosis, and the use of PEG in colonoscopy bowel preparation is associated 
with an increased risk of acute renal failure in patients over 50 [40, 41].  There is also 
evidence that repeat administration of PEGylated particles can lead to increased clearance 
rate, likely related to anti-PEG IgG and IgM antibodies [42, 43].  The structure of the PEG 
molecules, properties of the molecule being PEGylated, and method of PEGylation all play 
a role in determining immunogenicity [43].   
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Direct PEGylation confers benefits in both protein absorption and systemic stability 
(described later in this paper).  As an example, insulin PEGylated with a 750 Da version 
of PEG was formulated into a mucoadhesive tablet.  After oral administration, insulin 
activity was demonstrated by the observed drop in blood glucose levels of approximately 
50% 3 hours after administration.  Additionally, some activity of the orally administered 
insulin was seen up to 30 hours after administration [44].  PEGylation of another peptide, 
salmon calcitonin (sCT), resulted in resistance to intestinal enzymes, a nearly 6-fold 
increase in intestinal absorption, and slowed systemic clearance compared to the 
unmodified version of sCT [45]. 
Vitamin B12 has been used to increase the oral absorption of a number of 
therapeutic proteins including G-CSF, EPO, insulin, and LHRH [46].  By fusing 
therapeutic proteins to vitamin B12, it is possible to take advantage of the binding of 
vitamin B12 to intrinsic factor (IF), followed by the receptor-mediated absorption of the 
vitamin B12-IF conjugate.  However, this system is limited by the quantity of B12 that can 
be absorbed, GI degradation, decreased activity of the protein therapeutic due to steric 
hindrances, and loss of IF affinity for conjugated vitamin B12 [46].  For more information 
on the use of B12 to improve the oral delivery of protein and peptides, see the review by 
Petrus et al. [47].  
Protein lipidization is another method which increases the bioavailability of orally 
administered proteins.  Fatty acid conjugates of polypeptides show improved transport 
across biological membranes, higher stability, and longer plasma half-lives [48, 49].  
Salmon calcitonin was lipidized using reversible aqueous lipidization (REAL), and thus it 
is categorized as a prodrug in this case [49].  Compared to the free sCT, the REAL-sCT 
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showed increased absorption and a 19 times higher AUC value [49].  Caprates, medium-
chain fatty acids, promote paracellular diffusion of Class III (highly soluble, low 
permeability) molecules such as peptides [50].  In addition, triglycerides can be used to 
evade first-pass metabolism [50].  While irreversible methods of lipidization allow for 
increased membrane permeability, the activity of such modified proteins may be 
diminished due to steric issues with the fatty acid chain [50]. 
Recently, stapled peptides have garnered interest due to their enhanced biochemical 
properties in the context of drug delivery.  More specifically, these are alpha helical 
peptides which contain a synthetic, hydrocarbon backbone linking various residues [51].  
This backbone, known as the staple, locks the conformation of the peptide, increasing its 
helicity and stability in solution [52].  As an example, Walensky et al. have shown the 
ability of a hydrocarbon-stapled BH3 helix to increase apoptosis in vivo [53].   The 
enhanced stability of these peptides, along with increased cellular penetration capabilities, 
makes these molecules ideal candidates for future study in peptide delivery.     
A final method of peptide modification to increase oral bioavailability is the 
substitution of natural L-amino acids with D-amino acids.  One study showed that a variety 
of peptides cleaved by chymotrypsin, elastase, papain (a cysteine protease found in 
papaya), pepsin, trypsin, and carboxypeptidases are cleaved minimally or not at all by these 
enzymes when certain residues were replaced with D-amino acids [32, 54].  Tugyi et al. 
investigated D-amino acid substitutions in MUC2, a mucin glycoprotein [55].  The authors 
noted that the substituted peptide demonstrated high resistance to proteolytic degradation 
in vitro in both human serum and lysosomal preparations.  Their work demonstrated that 
simultaneously modifying both N- and C-terminal regions with D-amino acids conferred 
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the greatest stability increases [55]. 
The above mentioned direct modifications of peptides and proteins are key 
strategies that have been implemented to increase stability and oral bioavailability.  Many 
other direct modifications have been carried out, including certain prodrug methods, in 
Table 2.3.  
In addition to direct modifications, another method to increase oral peptide 
bioavailability is to coadminister with enzyme inhibitors.  These enzyme inhibitors are 
usually more effective in the large intestine than the small intestine due to the large quantity 
and variety of proteases in the small intestine [56].  A leading enzyme inhibitor is soybean 
trypsin inhibitor, FT-448, a potent and specific inhibitor of chymotrypsin [56].  When 
coadministered with insulin to rats and dogs, levels of immunoreactive insulin rose 
proportionally to a decrease in blood glucose levels.  Further, it is thought to play some 
role in increasing peptide absorption [56].  
 
Enzyme Inhibitors 
Aprotinin, originally branded as Trasylol™ and used to reduce bleeding during 
complex surgeries, is another enzyme inhibitor used [57].  When administered with insulin 
intraileally, blood glucose decreased by 30% over the next 3 hours compared to 
administration of insulin alone [57].  Other enzyme inhibitors are summarized in Table 2.4.  
An alternative method to inhibit enzymes is to alter the pH at the site of action of the 
enzymes [58].  Most enzymes in the stomach, including pepsin, are only active at low pH 
(around 2) [59].  Therefore, if the pH in the stomach is increased, the enzymes are no longer 
able to degrade the peptides.  Conversely, enzymes in the intestines often work at a higher 
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Table 2.3. Direct modifications of peptides and proteins. Overview of direct 
modifications made to peptides and the resulting change in bioavailability.  PEG: 
Polyethylene glycol; AA: Amino acid; CSA: Cyclosporine; IFN: Interferon; MUC2: Mucin 
2; IgG: Immunoglobulin G; G-CSF: granulocyte colony stimulating fator; EPO: 
erythropoietin; LHRH: lutenizing hormone releasing hormone; DP3: octapeptide (Glu-
Ala-Ser-Ala-Ser-Tyr-Ser-Ala); AUC: Area under the curve 
 











Reduced hydrophilicity, decreased 
conformational flexibility, 
enhanced membrane permeability, 
and resistance to proteolysis [3, 34, 
35] 





Resistance to intestinal enzymes, 
slowed systemic clearance, 
increased intestinal absorption, [44, 
45] 
Prodrug IFN-B-1b Prolonged activity, dimished IgG 
response, improved protection from 
enzymatic degradation [44, 60] 
B12 
Conjugation 
ε position on the 
Corrin ring 
 Albumin, G-CSF, EPO, LHRH and 
analogues, DP3, dextran 
nanoparticles [47] 
5’-hydroxy on α tail  IFN, insulin [47] 
Phosphate unit of the 
α tail 
 Albumin, γG-globulin [47] 





AUC 19x higher than unmodified, 






Improved oral bioavailability, 
improved resistance to trypsin and 
leucine aminopeptidase, enhanced 
membrane permeability [61] 
D-amino 
acids 
6 out of 11 L-AA 
substituted for D-AA 
MUC2 Resistance to chymotrypsin 
proteolysis, elastase, papain, 




Increased permeation of Caco-2 
cell layer; active in plasma [62] 
Perbuytrylation Glycovir Increased bioavailability [63] 
Stapling Hydrocarbon  Increased bioavailability, resistance 





Table 2.4. Enzyme inhibitors, their targets, and effects on peptide delivery.  An 
overview of potentially clinically relevant enzyme inhibitors.  
Ala: Alanine; Leu: Leucine 
 
ENZYME INHIBITOR MOLECULES 
INHIBITED 




Chymotrypsin Enhanced intestinal 
absorption of insulin in rats 
and dogs 
Suppressed digestion of 
insulin by pancreatic enzymes 
[56] 





insulin with aprotinin led to 
decrease in blood glucose of 
30% compared to controls 
[57] 
PUROMYCIN Serine and 
metallopeptidases  
Improved stability of leucine 
encephalin and stability, 
permeability of D-Ala2, D-
Leu5 enkephalin (DADLE) 
[65-67] 
N-ACETYLCYSTEINE Inhibits aminopeptidase 
N and had mucolytic 
properties[68, 69] 
 
BACITRACIN Trypsin and pepsin, 
aminopeptidase N[69, 
70] 
Used to increase delivery of 













pH; therefore, lowering the pH can decrease the activity of these enzymes [71, 72].  These 
protease inhibitors do have shortcomings.  First, they can disrupt the normal absorption of 
dietary peptides and may induce toxic shock after prolonged therapy [73, 74].  It is believed 
this may cause the body to increase production of these proteases, which may lead to 
hypertrophy and hyperplasia of the pancreas [68].  The inhibitors themselves may also be 
toxic and damaging to the GI tract after prolonged administration [68].  Indeed, the 
majority of enzyme inhibitors are highly toxic.  Table 2.4 summarizes enzyme inhibitors 
with some promise of therapeutic translatability.   
 
Absorption Enhancers 
The optimal absorption enhancer should be reversible, nontoxic at the effective 
concentration, and provide a rapid permeation enhancing effect on the intestinal cell 
membrane. One such compound class of absorption enhancers is chitosans.  Chitosans are 
nontoxic, biocompatible, US-FDA approved polymer derivatives of chitin which enhance 
the absorption of hydrophilic macromolecule drugs [75].  Additionally, due to their high 
molecular weight, they are minimally absorbed from the gut, limiting the possibility of 
systemic side effects [76].  It is thought that varying degrees of deacetylation of chitin 
confer different amounts of absorption enhancement, with >80% deacetylation affording 
the greatest promoter effect in cell culture [77].  Chitosans have been used to enhance the 
absorption of such molecules as atenolol, insulin, and 8-R-vasopressin [76].  Further, 
chitosans appear to be quite safe at their effective concentration [75, 78].  Chitosans work 
by increasing paracellular permeability.  By binding tightly to the epithelium via positive 
charges, chitosans cause redistribution of cytoskeletal F-actin and the zonula occludens 1 
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[79].  Chitosans are limited by their ability to diffuse across the mucous layer, as evidenced 
by their decreased activity on mucus-producing cells [80].  In vivo studies with chitosans 
demonstrated a three-fold increase in octreotide absorption when the two were 
coadministered into the duodenum [76].  Another study with trimethyl chitosan chloride 
(TMC), a chitosan derivative, had many favorable characteristics.  TMC was able to 
reversibly interact with TJs, leading to widening of the paracellular route and at the same 
time did not damage cell membrane or alter the viability of intestinal epithelial cells.  In 
vivo studies in rats showed that it was able to increase the oral bioavailability of a peptide 
when the two were coadministered [75].  Overall, chitosans and their derivatives are a 
promising class of absorption enhancers. 
Another class of absorption enhancers showing potential includes the medium 
chain fatty acids [81].  C8, C10, and C12 fatty acids (caprylate, caprate, and laurate, 
respectively) can enhance paracellular permeability of hydrophilic compounds.  First, 
caprate is thought to work by inducing dilation of TJs [82].  Interestingly, the lowest 
concentration which enhanced absorption was near the critical micelle concentration 
(CMC) of each fatty acid [81].  The order of increased absorption in vivo is 
caprate>laurate>caprylate.  Sodium caprate (C10) is the most studied of the medium chain 
fatty acids.  It is thought to increase absorption of hydrophobic molecules via the 
paracellular and transcellular route [83].  Unfortunately, a study showed that it can only 
significantly increase absorption for molecules up to 1200g/mol, or 1.2 kDa (such as 
octreotide) [84].  At the effective dose of 13mM, sodium caprate is nontoxic to epithelial 
cells [84].   
Lectins are another type of absorption enhancers which have many of the 
52 
 
characteristics of the ideal absorption enhancer.  Lectins are proteins that specifically 
recognize and bind to sugar complexes attached to proteins and lipids [85].  Lectins are 
also naturally resistant to proteolytic breakdown, making inactivity before reaching their 
site of action unlikely [86].  They can be used to target luminal surfaces of the small 
intestine and trigger vesicular transport into or across epithelial cells [85].  Lectins are also 
mucoadhesive which further leads to increased absorption [18]. 
Toxins can also be used for absorption enhancement, so long as they do not cause 
permanent cellular damage.  ZOT, or zonula occludens toxin, is one such compound.  ZOT, 
a 45 kDa toxin made by Vibrio cholerae, has been shown to increase the permeability of 
small intestine mucosa by reversibly affecting the structure of TJs [87, 88].  ZOT binds to 
ZOT receptors on the luminal surface of the intestine and causes cytoskeletal 
rearrangement related to changes in protein kinase C and binding to β-tubulin [88, 89].  TJs 
can be perturbed enough to allow the transport of agents across the intestinal mucosa, 
although the increased bioavailability of insulin was only 20% [90].  In a study with Caco-
2 cells, incubation with 4µg/mL ZOT for 30 minutes increased the permeability to insulin 
by 6.3-fold. [90]  Mediation of TJs may not be the only method by which ZOT works; a 
study demonstrated that a fragment of ZOT was able to increase the bioavailability of 
hydrophobic drugs by interacting with PGP [91].  Additional work has been done to 
determine the smallest portion of ZOT which maintains activity [92]. 
Recently, coadministration of cell-penetrating peptides (CPPs - described later in 
more detail) with therapeutic peptides has been attempted in order to increase absorption 
of the therapeutic.  In one study, insulin coadministered with CPPs consisting of 6-10 
repeats of arginine led to increased GI uptake of insulin [93].  Interestingly, the study 
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investigated both D- and L-arginine-based CPPs, and the D-based CPPs allowed for greater 
increases in insulin absorption, assumed to be due resistance of D-amino acids to proteases 
[93].  It is important to note that the CPP was not fused to insulin; rather, they were 
coadministered.  A follow-up study demonstrated that electrostatic interactions between 
insulin and the CPP were responsible for the enhanced absorption of insulin [94].  Another 
study revealed that the CPP penetratin was best able to increase ileal insulin absorption 
[95].  Penetratin consists of basic amino acids (lys, arg) along with some hydrophobic 
regions.  Use of CPPs as absorption enhancers represents a relatively new area of research 
which have the potential to add weapons to the absorptive enhancement arsenal.  
Other classes of absorption enhancers have lost favor in recent years due to 
irreversible epithelial damage [96].  Surfactants such as SDS were shown to cause 
increased permeability of the GI tract to hydrophilic compounds, but also cause altered cell 
morphology and cell membrane damage [97].  SDS shortened microvilli of cells and 
produced actin disbandment, structural separation of the TJs, and damage to the apical cell 
membrane with even limited exposure [98].  Certain in vivo rat studies support the increase 
in absorption and revealed the damage caused to be reversible [99].  Bile salts such as 
sodium cholate and deoxycholate were originally seen as safe and effective at increasing 
drug absorption.  However, it is now understood that  these particles are damaging after 
long-term use [100]. 
 
Carrier Systems 
Many drug carrier systems are currently being developed in an attempt to increase 
the oral bioavailability of peptide drugs.  Some of these systems contain a combination of 
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components listed above, while others have novel mechanisms.   
The first group of carrier systems consists of hydrophilic mucoadhesive 
polymers(polyacrylates, cellulose, chitosan), which can be altered to suit the needs of the 
peptide/protein being delivered [101].  While chitosan has already been discussed under 
the absorption enhancers category, it has also been combined with EDTA in order to create 
a resin which binds bivalent cations [102].  It is thought that bivalent cations are essential 
for the activity of proteolytic enzymes; in fact, zinc proteases, carboxypeptidases, and 
aminopeptidases were strongly inhibited by this system, but serine proteases, trypsin, alpha 
chymotrypsin, and elastase were not inhibited [102]. 
Thiomers, thiolated polymers, have also been used as drug carrier systems.  These 
mucoadhesive polymers display thiol-bearing side chains; disulfide bonds form between 
the polymer and cysteine rich protein domains in the mucous glycoprotein layer.  These 
polymers are available in both cationic and anionic varieties and can increase 
mucoadhesive properties of gels by up to 140-fold [103].  When adhered in the small 
intestine, mucoadhesion allows for a steeper concentration gradient across the epithelial 
barrier, which may lead to increased passive drug uptake and prolonged therapeutic effect 
[103].  
Next, polymer matrices can be used to protect proteins from proteolysis and 
antibody neutralization, resulting in increased protein activity in vivo [104].  It is very 
important that interaction between the protein and matrix be optimized; too little attraction 
and the protein will not be immobilized on the gel; too great an attraction will cause the 
protein to remain in the gel and thus not become systemically available.  A sustained release 
system which protects the protein in the GI tract can be developed by tuning the cross-
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linkage and electrostatic interactions between matrix and protein [104]. 
Nanoemulsions are another carrier system for oral protein therapeutics.  
Nanoemulsions are defined as oil in water (o/w) or water in oil (w/o) emulsions with mean 
droplet diameter ranging from 50 to 1000 nm.  The average droplet size is usually between 
100 and 500 nm [105]. Generally, these emulsions are made from surfactants approved for 
human consumption and are generally recognized as safe.  Nanoemulsions have a much 
higher surface area and free energy than macroemulsions, thus making them an effective 
transport system.  Further, nanoemulsions do not cream, flocculate, coalesce, or sediment.  
One such system in development is the “Self-Nanoemulsifying Drug Delivery System ,” 
or SNEDDS. To test the concept, FITC-labeled β-lactamase (BLM) was loaded into 
SNEDDS through solid dispersion.  After an O/W emulsion was formed via addition of 
water, the nanoemulsion was able to increase transport of FITC-BLM across MDCK 
monolayer of cells [106].  In vivo studies showed a significant increase in SNEDDS-BLM 
absorption compared to free BLM [106]. 
Hydrogels are a network of cross-linked water-soluble polymer chains which are 
insoluble in water but have water as their dispersion medium.  The porous nature of 
hydrogels can be finely tuned to allow for drug loading into the hydrogel.  Further, 
pharmacokinetic properties for release of the loaded drug can be adjusted to the 
requirements of individual drugs [107].  Hydrogels can designed to deliver drugs to four 
sites after oral ingestion: mouth, stomach, small intestine, or colon [107].  Newly developed 
homo- and copolymeric hydrogels are capable of protecting and delivering peptides and 
protein therapeutics [107].  For an overview on hydrogels, see Bindu Sri et al., and for 
more detail on the use of hydrogels for the oral peptide drug delivery, the review by Peppas 
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et al. is helpful [107, 108]. 
While liposomes system have potential as oral drug delivery, there is a concern with 
stability of the vesicles under the physiologic conditions of the GI tract [109].  Adding to 
the problem, mucus may act as a barrier by blocking the diffusion oPf liposomes to the 
epithelial layer [110].  Despite this, orally administered liposomes have demonstrated some 
successes.  Calcitonin was administered in a chitosan-aprotinin coated liposome and 
showed an increased pharmacological effect compared to free calcitonin [111].  
Cyclosporine has also been delivered in liposomes; the egg lectin-cremophore-lactose 
liposome containing CSA had 9 times the bioavailability of free CSA and 4 times that of 
the microemulsion on the market [112].  PEG, coating, enteric encapsulation, and the use 
of archaeosomes have been proposed to decrease degradation of the liposome in the GI 
tract [113]. 
Nanoparticles are solid particles with sizes in the range of 10-1000 nm [114].  
Nanoparticles allow for the encapsulation of proteins inside a polymeric matrix, thus 
protecting them against hydrolysis and enzymatic degradation [114].  These systems can 
be tuned in order to maximize encapsulation efficiency, bioavailability, and retention time 
[115].  Nanoparticles, however, have a difficult time being absorbed from the GI tract; 
studies have shown that cells lacking mucus (including M cells and Peyer’s patches in 
general) are best at absorbing nanoparticles [114].  Particles of 50 and 100 nm 
demonstrated the greatest absorption and detection in intestinal mucosa [116].  Further, 
nanoparticles smaller than 100nm show higher extents of uptake by absorptive enterocytes 
while those over 500 nm will rarely be taken up by absorptive enterocytes [114].  
Nanoparticles are often made from poly(lactic acid) (PLA), poly(lactic-co-glyclic acid) 
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(PLGA), chitosan, gelatin, and poly-alkyl-acyanoacrylate, all of which are nontoxic, 
nonthrombogenic, nonimmunogenic, noninflammatory, stable in blood, biodegradable, 
avoid the reticuloendothelial system (RES), and are applicable to various biologics such as 
protein, peptides, and nucleotides [115].  While there is minimal scientific data on the 
toxicity of nanoparticles, their size makes exposure during manufacturing almost 
guaranteed [117]. Impaired lung function and other respiratory symptoms have been seen 
in workers who were exposed to nanoparticles [117]. Intravenous administration of 
nanoparticles is followed by increased synthesis and release of cytokines.  Further, 
nanoparticles passively target the liver through uptake by Kupfer cells, again followed by 
an inflammatory response [117]. Generally, the toxic effects of nanoparticles are not fully 
understood, and care must be taken with the manufacturing and use of nanoparticles as 
therapeutic agents. Table 2.5 provides some details regarding the various polymers used to 
make nanoparticles. 
Nanoparticles (NPs) can be targeted to certain sites based on particle size, surface 
charge, surface modification, and hydrophobicity [115].  Surface charge is particularly 
important for cell internalization, as cationic surfaces increase the rate and extent of 
nanoparticle internalization [115].   Carboxylated polystyrene NPs show decreased affinity 
to intestinal epithelia and M cells compared to neutral and positively charged polystyrene 
nanoparticles [118].  While hydrophobic polymer-based nanoparticles are better absorbed 
than their hydrophilic counterparts [114], in order to avoid opsonization and the 
mononuclear phagocytic system (MPS), the use of hydrophilic surfaced nanoparticles is 
preferred over traditional hydrophobic-surfaced nanoparticles [115, 119].  Interestingly, 




Table 2.5. Polymer carrier systems. Commonly used polymers for construction of 
nanoparticles, their biocompatibility, and use in peptide delivery 
BSA: Bovine serum albumin; OGTT: Oral glucose tolerance test; AmB: Amphotericin B; 
PLGA: Poly(lactic-co-glyclic acid); PLA: Poly(lactic acid) 
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Degraded by hydrolysis  Preparation of long-term 
implantable device,  
Insulin loaded with 96% 
efficiency, improved 
response to oral glucose 
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Has mucoadhesive 
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Amphotericin B loaded 
PCL nanoparticles 2-3x 
more effective than free 
AmB [121, 122] 
CHITOSAN Nontoxic, biocompatible Insulin loaded chitosan 
nanoparticles enhanced 
intestinal absorption of 
insulin through a 
combination of insulin 
internalization in 
enterocytes and insulin-
loaded particle uptake by 
Peyer's patches [123] 
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PLGA nanoparticles with 
influenza HA incorporated 
throughout the matrix, 




uptaken by absorptive enterocytes and M cells [114, 128]. 
Surface modifications such as PEG can create a steric barrier and reduce clearance 
by circulating macrophages in the liver as well as by the MPS [115].  PEG-coating of 
nanoparticles increases blood circulation half-life as well as reducing interactions between 
the nanoparticles and digestive enzymes [129].  Lectins have been conjugated to 
nanoparticles which led to increased transport across intestinal mucosa, especially via M 
cells of Peyer’s patches [114, 115].  Finally, higher molecular weight polymers will release 
the peptide more slowly than lower molecular weight polymers [115]. 
Solid lipid nanoparticles (SLN) are solid lipids which are stabilized with an 
emulsifying layer in an aqueous dispersion (Figure 2.3).  The colloidal size ranges between 
50 and 1000nm [109].  This system avoids the use of organic solvents and has the capacity 
to allow fast, effective, large-scale manufacturing of high-concentration suspensions.  This 
system can be used to encapsulate peptides and proteins and thereby protect them against 
enzymatic degradation [130].  Another benefit of SLNs is that the drug can be incorporated 
into the matrix, onto the shell, or into the core of the particle [109].  A lectin-modified and 
insulin-coated SLN was able to deliver insulin to the system after administration to the 
small intestine [131]. SLNs have also been used for controlled release of sCT [132].  The 
systemic stability and GI absorption of SLNs and nanoparticles as a whole make them a 
promising protein carrier system; research in this field continues to enhance the likelihood 
for oral delivery of systemically-active peptides. Many companies are attempting to 
develop carrier systems which will be able to deliver a wide variety of therapeutics with 
minimal modification [73].  Examples include Emisphere’s Eligen ™ system which has 






Figure 2.3.  Solid lipid nanoparticles (SLN).  SLN has a solid lipid core and is coated 
with surfactant.  Targeting moieties may be added to decorate the surface of the SLN.  











SNAC (n-(8-[2-hydroxylbenzoyl]amino)caprylic acid) can be used to orally deliver active 
peptides into circulation [133, 134].  The peptide/protein therapeutic is mixed with SNAC 
which creates a noncovalently linked drug-carrier complex.  The complex is highly 
lipophilic and is proposed to be able to directly cross the epithelial membrane.  After 
absorption, the complex dissociates by simple dilution, and the therapeutic is released, 
unchanged and in its active conformation [73, 133].  This system has shown promise in 
both human and animal models for the oral delivery of insulin, human growth hormone 
(hGH), and sCT [134]. 
A second such system is the “gastrointestional mucoadhesive patch system” or GI-
MAPS, depicted in Figure 2.4.  The GI-MAPS system is composed of four layers contained 
in an enteric capsule, which combined result in protection of the protein in the GI tract as 
well as increased absorption.  The backing is made of ethyl cellulose, while the surface 
layer is made of an enteric, pH sensitive polymer, in this case Eudragit L100.  The middle 
layer is a cellulose membrane which contains both the drug and absorption enhancers.  The 
surface layer is attached to the middle layer via an adhesive layer made of Hiviswako 103 
polymer [135].   
When the capsule is swallowed, the enteric coating dissolves in the small intestine. 
Once this layer dissolves, the mucoadhesive layer of the patch is exposed.  The patch 
therefore adsorbs to the mucus membrane of the small intestine, exposing the drug and 
absorption enhancer to the epithelial surface.  When the patch attaches, it provides 
increased contact time, allowing more of the drug to be absorbed.  Additionally, a large 
concentration gradient is created across the epithelial cells, increasing the amount of drug 








Figure 2.4: GI-MAPS system.  The system contains 4 layered films in an enteric capsule.  
Layer 1 is the backing layer; layer 2 is the middle or drug layer; layer 3 is the adhesive 























Table 2.6. Multicomponent carrier systems.  These systems are composed of multiple 
parts and chemicals.  They are designed to allow for the delivery of a variety of peptides 
and proteins.  GI-MAPS: Gastrointestinal mucoadhesive patch system; SNAC: n-(8-[2-
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list of similarly functional systems (adapted from [73]). 
The above has been a broad overview of the issues associated with oral 
administration of peptide and protein therapeutics.  Many systems which increase stability 
and absorption of these therapeutics have been described.  Until a more widely applicable 
system is developed, every protein therapeutic will require a unique system made of 
combinations of the above if the drug is to be orally bioavailable.    While the oral route is 
a preferred method of administration, other routes, too, have their benefits. The next section 
will address the issues with transdermal peptide and protein delivery. 
 
Transdermal Delivery 
 Delivering peptides transdermally allows the avoidance of both GI degradation and 
hepatic first-pass metabolism of short half-life drugs while still allowing administration via 
an easily accessible, noninvasive route.  This not only diminishes the amount of potential 
drug-drug interactions with combined therapies, but can also lead to better patient 
compliance (compared to IV injection) due to the ease of use, self-administration, and less 
frequent dosing characterized by the prolonged, continuous and rate-controlled drug 
release unique to these systems [136-140]. 
 First and foremost, the most important barrier for transdermal delivery is the skin 
itself [136].  Drugs that have been delivered transdermally for some time now, namely 
nicotine,  estrogen,  and  scopolamine,  among  others,  are  all  small,  highly  hydrophobic 
molecules.  Historically, it has been shown that the skin tends to keep out drug molecules 
greater than 500 Da [141], especially those molecules of hydrophilic nature [142].  After 
all, the main biological function of the skin is to deny entry to foreign objects.  Therefore, 
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bypassing skin for drug entry is a necessary step to successful transdermal delivery [143]. 
 Anatomically, the skin is made up of three major layers.  The outermost portion, 
and first line of defense to drug entry, is the stratum corneum [144].  This layer, mainly 
comprised of dead cells (keratinocytes), is approximately 10-15 μm thick and surrounded 
by a lipid extracellular matrix.  Below the stratum corneum lies an avascular layer, 
approximately 50-100 μm thick, known as the viable epidermis.  Taken together, these two 
layers are known as the full epidermis.  Below the full epidermis is the first sign of 
vasculature, present in a layer known simply as the dermis [140].  A fibrous layer, 
approximately 1-2mm thick, the dermis is comprised of large capillary beds which are the 
site of drug entry into the circulation [145].   
 Due to these obstacles provided by the skin, successful transdermal delivery of 
large, potentially hydrophilic peptides requires some type of physical and/or chemical 
enhancement.  Conventional enhancements in transdermal delivery generally aim to bypass 
the main physical barrier, the stratum corneum [138, 146-150].  Direct entry into the 
dermis, despite being the most direct way to get the drug into circulation, is often avoided 
as penetration of this layer would lead to patient bleeding and possible disruption of nerve 
endings [148].    
 Because the traditional transdermal patch is used solely to deliver small, 
hydrophobic drugs, and not peptides, it will not be discussed in this section.  Instead, many 
of the currently “in-development” transdermal enhancement methods will be briefly 
described, including microneedle technology, electroporation, iontophoresis, 





 Microneedle technology involves the use of small needles which create small pores 
in the skin, allowing drug passage across the outermost physical barrier [138].  Because 
one of the overall goals of transdermal delivery is to increase efficiency while still 
maintaining an easy, noninvasive technique, these microneedles are designed to breach 
only the stratum corneum [148].  By not reaching as far as the viable dermis, both the 
capillaries and nerve endings are avoided, leading to a painless feeling for the patient.  
These needles have been created using a number of materials, including silicon, various 
metals, or biodegradable materials such as some polymers and sugars [145].   
 As described by Herwadker and Banga [137], multiple microneedle designs and 
drug introduction routes have been tested for efficient delivery .  One such method involves 
a two-step approach, where the needles are used to puncture the skin to create pores, 
followed by topical administration of the drug.  Another method includes coating the 
microneedles themselves with drugs, thus allowing the drug to then enter the body as the 
skin is treated with the needle.  A third method includes encapsulating the drug in 
biodegradable microneedles, slowly releasing the drug as the needles degrade.  Lastly, a 
final method includes creating hollow needles, through which drug can be infused 
following puncturing of the skin.  Microneedles can be introduced via physical injection 
on the skin or in the form of a patch.  One example utilizing this technology comes from 
Zosano Pharma, who have developed a patch containing drug-coated microneedles capable 






 Like microneedle technology, thermal ablation aims to permeabilize only the 
stratum corneum, avoiding a breach of the deeper capillary and nerve-containing tissue 
layers [150].  However, instead of using needles to perforate the skin, this technique relies 
on short pulses of high heat (around 100°C) to create small, reversible channels in the 
micron size-range [151].  Following the short bursts of heat, drug can be applied to the 
treated area for entry into the circulation.  Multiple systems have been designed to 
successfully deliver drugs via thermal ablation, including PassPort® (Nitto Denko) and 
ViaDor® (Syneron Medical Ltd).  While these systems have shown success with smaller 
drugs, delivery of peptides is still under study [145].     
 
Electroporation 
 Electroporation utilizes very short pulses of high voltages (between 10 and 100 V) 
to perforate the skin.  Similar to microneedles and iontophoresis, application of 
electroporation breaches only the stratum corneum, characterizing it as another 
noninvasive method for drug introduction [152].  Instead of simply targeting the layer of 
dead cells, this method targets the surrounding lipid bilayers which are spread out 
throughout this layer.  Application of electric current disrupts the structure of these lipids, 
allowing molecules to penetrate the skin.  In addition, delivery of drug can be increased 
using this method by increasing the voltage, number of pulses, and duration of pulses to 
levels still viewed as safe for the patient [137].  Due to the high complexity of these 
systems, no peptides have been FDA approved for delivery by electroporation.  However, 
multiple DNA-based vaccines are in clinical trials, which, if successful, could pave the way 
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for other peptide-based vaccines. 
 
Sonophoresis 
 Sonophoresis, also referred to as cavitational ultrasound, relies on the application 
of sound waves to the skin to increase its permeability.  Like electroporation, sonophoresis 
achieves this task by targeting the lipid bilayers imbedded in the stratum corneum [137].  
Sound waves, generally between 20-100 kHz, are believed to cause an increase in pore 
sizes on the skin (increased fluidity in these lipid bilayers), thus allowing drug penetration 
transcellularly through stratum corneum [151].  Though nothing is currently FDA 
approved, delivery of insulin for Type I diabetes using the U-Strip system (Transdermal 
Specialties, Inc.) is presently in clinical trials, parts of which are expected to be completed 
within a year [153].     
 
Iontophoresis 
 Not all methods utilized for transdermal peptide delivery require physical 
disruption of the skin’s outer barrier.  Iontophoresis is one of those methods, which instead 
uses principles of both electrorepulsion (for charged peptides) and electroosmosis 
(uncharged peptides) to act on the drug molecules themselves rather than the skin [137]. 
Generally speaking, iontophoresis utilizes a device placed on the skin capable of generating 
an electric current, similar to a battery.  When delivering charged peptides (negatively 
charged peptides for instance), the battery builds up a strong negative charge at the anode, 
which would be placed on the same portion of the skin as the drug molecules.  Utilizing 
charge-charge repulsion, this anode will drive the negatively-charged peptide into the skin 
69 
 
[136, 154].  Using this method, the rate of drug release can be controlled as the release 
(entry into the body) is directly proportional to the current being administered on the skin 
[151].  Although peptides have yet to see FDA-approval for delivery via iontophoresis, the 
system has been fine-tuned to deliver smaller molecules such as lidocaine (LidoSite®, 
Vyteris).  In addition, iontophoretic peptide delivery, including delivery of gonadotropin 
releasing hormone and insulin, has reached clinical trials on multiple occasions [145].   
 
Biochemical Enhancement 
 A final method involves the use of biochemical molecules to enhance permeation 
of peptide drugs across the skin.  The ultimate goal in using biochemical enhancers is to 
increase the permeability of the skin, which provides a path for peptide drug delivery into 
the circulation [151], while remaining nontoxic, nonirritating, and nonallergenic [144].  
One such peptide used to enhance skin permeability is magainin, a 23 amino acid peptide 
known to form pores in bacterial cell membranes [155, 156].  While previously shown to 
increase the permeability of small molecules, its use for peptide delivery enhancement still 
requires optimization [157].  In addition, recently, work by Ruan et al. showed the ability 
of a small peptide known as TD1 to increase the transdermal penetration capability of 
human epidermal growth factor (hEGF) when fused together [142, 158].  This fusion 
system involving TD1 could have major implications in the near future for delivering 
hydrophilic peptides transdermally.    
 To summarize, all of the methods described above aim to make the drug delivery 
process as easy and as painless as possible.  Painless, in these cases, requires avoiding a 
breach of the viable dermis layer of the skin, which includes vasculature and nerve endings.  
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However, other barriers still exist, making this delivery process more efficient.  Despite 
moderate success seen using the previously described physical and chemical enhancement 
methods, a recent study suggests that bypassing more than simply the stratum corneum is 
necessary for the most efficient transdermal delivery [140].  In addition, despite displaying 
low activity compared to other locations in the body, proteases do exist on the skin, adding 
another challenge to transdermal delivery of peptides. 
 
Other Delivery Routes 
 While this review has focused on delivery of peptides by oral and transdermal 
routes, delivery by other routes is also currently being researched.  The next section of the 
review will give a brief overview and recommendations for readings on intranasal, buccal, 
pulmonary, and rectal administration of peptide therapeutics.  These routes of 
administration are shown in Figure 2.1. 
 The intranasal route for peptide drug delivery is an area which has already had some 
successes.  For instance, desmopressin, calcitonin, and the seasonal influenza vaccine are 
already available via the intranasal route [159], [160].  Advantages of the nasal route over 
injected medications include increased patient convenience and comfort, elimination of 
needle-stick related injuries and infections, and decreased syringe-related medical waste 
[160].  Disadvantages include nasal irritation, limitations on volume and milligram amount 
of drug that can be delivered nasally, the rapid  renewal of nasal epithelium, acidic pH, 
endo- and exopeptidases, and large interpatient variability in absorption [160].  While the 
nasal route has traditionally been thought to be an option only for small molecules, highly 
effective and nonirritating absorption enhancers have been developed [161].  For a more 
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thorough review on intranasal peptide delivery, see Illum et al. [159]. 
 The buccal route, administration of drug through the mucosal membranes lining the 
cheeks, is another option for peptide delivery [162].  Drugs delivered by the buccal route 
are placed in the mouth between the gums and cheek [163].  Buccal delivery has many 
advantages including bypassing of the GI tract and possibly first-pass metabolism, ease of 
use, rapid onset, large contact surface area, and is generally amenable to the delivery of 
hydrophilic macromolecules [163, 164].  There are limitations to buccal delivery and 
patient adherence such as irritation of the mucosa, low permeability to peptides, and bitter 
taste of many buccal drugs [163].  Absorption enhancers and bioadhesive polymers are 
being used to resolve these problems.  Oxytocin, insulin, sCT, and GLP-1 have all been 
successfully delivered via the buccal route [163, 164].  For further reading on buccal 
peptide delivery, see Mujoriya et al. [164]. 
 Rectal administration of drugs, while not patients’ top choice, is sometimes 
necessary if other routes of administration (such as oral and IV) are not possible.  The 
rectum is comprised of a one layer thick epithelium complete with mucus and tight 
junctions [165].  While there are no villi, the surface area for drug absorption is 
approximately 200-400 cm2 [165].  Rectal administration is useful due to the minimal 
amount of proteases and avoidance of the first-pass effect.  However, the bioavailability of 
peptides is low without the use of absorption enhancers [165].  Both insulin and 
pentagastrin have been successfully delivered via the rectal route.  See Lakshmi et al. for a 
more in-depth discussion of rectal peptide delivery [165]. 
 The pulmonary route can be utilized for the systemic delivery of peptide 
therapeutics.  However, the anatomy of the lung creates many barriers to delivery including 
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respiratory mucus, mucociliary clearance, alveolar epithelium with TJs, pulmonary 
enzymes, and macrophages which secrete peroxidases and proteases [166].  The alveolar 
epithelium and capillary endothelium have high permeability to many lipophilic 
substances, but passage of large hydrophilic molecules is limited [166].  Many absorption 
enhancers and enzyme inhibitors that have been used to increase peptide absorption have 
been shown to be damaging to lung tissue [166].  Pulmonary delivery of insulin has been 
extensively studied and was US-FDA approved in 2006, but Pfizer discontinued production 
in 2007 due to poor sales [166, 167]. Calcitonin, hGH, parathyroid hormone (PTH), and 
desmopressin have also successfully delivered via inhalation [166, 168].  A complete 
review of pulmonary peptide delivery can be found in the paper by Agu et al. [168]. 
 
Systemic Peptide Stability and Site-Specific Delivery 
Unfortunately, once the peptide has gained entrance to the systemic circulatory 
system, the task is only halfway complete.  The protein must still reach its target site, and 
as many of the targets for protein drugs are intraceullular, this means transport through the 
circulation to the appropriate site, uptake by the appropriate cells, and activity of the protein 
inside these cells.  Therefore, the goals for the protein in the circulatory system include: 
avoidance of enzymatic degradation; opsonization and the RES; nonselective accumulation 
of the protein; maintenance of protein solubility and activity; distribution to the site of 
action with targeting to certain cell types; cellular uptake and release of the active protein.  
This portion of the paper will discuss many of the systems and methods mentioned earlier, 
but now focusing on issues within systemic circulation.  Some of the systems discussed are 
not amenable to oral or transdermal delivery and would necessitate IV delivery.  Strategies 
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discussed here include: stability enhancers, drug carriers, endosomal escape, and targeting 
moieties.  
 
Systemic Stability Enhancement 
Many of the stability enhancers discussed in the first portion of this review have a 
role in increasing the systemic stability of protein therapeutics as well.  For example, fatty 
acid conjugation leads to extended plasma half-lives, site specific delivery, and sustained 
release upon IV administration [50].  As these drugs are lipophilic, they will likely be 
solubilized and stabilized by albumin and other serum lipoproteins [50].  Furthermore, 
these fatty acids can be removed from the protein via chemistry based on pH, reduction, 
peptidases, or esterases [50].  Nonreversible lipidization is also an option, and has been 
shown to increase internalization and activity over nonlipidized counterparts [169]. 
 
PEGylation 
PEGylation has also been used as a systemic stability enhancer.  Direct PEGylation 
can aid in the stability of proteins for delivery, leading mainly to an increase in circulation 
time.  PEG molecules are highly hydrated, and this increased size leads to decreased 
glomerular filtration [37].  Moreover, PEGylation of proteins is thought to reduce 
proteolysis and opsonization [170].  PEGylation also reduces uptake by the RES, decreases 
the formation of antibodies against the protein, and decreases the apparent volume of 
distribution [37].  PEGylation, however, does have drawbacks. Due to the size of PEG, 
steric hindrance may decrease the activity of the protein.  Also, increased protein 
aggregation after PEGylation has been noted [37].  Chronic IV administration of PEG 
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proteins has unintended consequences such as vacuolation of the renal cortical tubular 
epithelium in lab animals.  However, these side effects were noted only after exposure to 
toxic, supratherapeutic doses of PEG.  Newer PEGylation methods such as living radical 
polymerization (LRP), free radical polymerization (FRP), atom transfer radical 
polymerization (ATRP) and reversible addition fragment transfer (RAFT) have allowed 
PEGylation with greater specificity and purity while making modification with PEG a 
simpler task [171]. 
 
Hyperglycosylation 
Hyperglycosylation has many of the same benefits as PEGylation, namely 
increased half-life, improved solubility, and reduced immunogenicity [37].  An additional 
benefit is that the oligosaccharides added via glycosylation are natural and biodegradable, 
thus skirting the possible problem of PEG accumulation with chronic administration.  The 
increased stability of hyperglycosylated peptides may be due to masking hydrophobic sites 
on the protein surface involved in noncovalent interactions that lead to aggregation, loss of 
activity, and/or increased immunogenicity [172].  Hyperglycosylated therapeutic proteins 
may however see decreased activity due to steric hindrances [37].  
 
Liposomes 
Liposomes show great potential as a carrier system for systemically administered 
protein therapeutics.  If constructed from biocompatible and biodegradable materials, 
liposomes cause very little to no antigenic, pyrogenic, allergic, or toxic reactions [173].  
Further, liposomes can be nonimmunogenic and have already shown delivery of a variety 
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of active protein therapies to cells in vivo [4].  Liposomes have been used to cross the blood 
brain barrier to deliver an active enzyme when injected in the tail vein of a rat [4, 174]. 
While first generation liposomes are easily cleared from the bloodstream and accumulate 
in Kupfer cells of the liver and macrophages in the spleen, advances have begun to reduce 
these problems [173].  To start, PEG-grafted liposomes have increased circulation time, 
reduced aggregation, and decreased capture by the RES.  PEGylated liposomes, or Steath 
™ liposomes, have been used to deliver the anthracycline chemotherapeutic doxorubicin 
and were able to deliver preferentially to the tumor site, likely via the enhanced 
permeability and retention (EPR) effect [175]. 
 
Fusogenic Modifications to Liposomes 
Many modifications have been made to liposomes to increase intracellular delivery 
of proteins.  When liposomes enter the cell they are contained in an endosome.  Particles 
smaller than 300 nm usually do not enter cells through the endosomal pathway, but 
particles of size 500-700 nm are often taken up by endocytosis [176]. If the liposome or 
the contents of the liposome do not escape the endosome, the endosome will deliver its 
contents to the lysosome, where the therapeutic peptide will be digested.  One method of 
facilitating endosomal escape is to include a pH-sensitive element into the liposome.  The 
pH in the endosome is around 5, and many systems take advantage of this relatively low 
pH to allow liposomes to escape the endosome [176].  Methods for endosomal escape 
include pore formation in the endosomal membrane, the proton sponge effect, and fusion 
with the endosomal membrane [176].    
Pore formation is based on a pore-forming or pore-enlarging molecule binding to 
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the rim of a pore in the endosome.  Once bound, the pore-forming agent reduces tension in 
the membrane, which then keeps the pore radius stable.[176].  Therefore, these agents act 
to stabilize naturally forming pores rather than to form pores de novo [177].  Pore forming 
compounds include penton base, cholera toxin, melittin (the major ingredient in bee 
venom), and Shiga toxin [178-181].  The pH buffering effect, also known as the proton 
sponge effect, occurs when the low pH in the endosome leads to the protonation of 
molecules contained inside the endosome.  If the molecule has a high buffering capacity, 
protonation leads to an influx of H+, Cl-, and H2O, resulting in osmotic swelling and 
eventual endosomal rupture [176].  Examples of molecules causing the proton sponge 
effect include gp41 with polyethyleneimine, poly (l-histidine), and chloroquine [182-185].  
Fusion within the endosome requires fusogenic peptides which undergo conformational 
changes with the lowered pH, allowing fusion with the lipid bilayer of the endosome [176].  
For example, a decrease in pH converts hemagglutinin, a protein in the capsid of the 
influenza virus, from an anionic hydrophilic coil to a hydrophobic helical conformation, 
followed by fusion of the viral membrane to the endosomal membrane.  Fusogenic peptides 
used in liposomes include the HA-2 subunit of hemagglutinin, influenza-derived diINF-7, 
the major envelope protein E of the West Nile Virus, glycoprotein H from Herpes Simplex 
Virus, and KALA based on HA-2 subunit of influenza hemagglutinin  [176, 178, 186-189].  
For a complete discussion of endosomal escape pathways, please see Varkouhi et al. [176].  
One more fusogenic agent worth mentioning in detail is 
dioleylphosphoethanolamine, or DOPE.  This peptide exhibits a conical shape due to its 
small and minimally hydrated headgroup compared to its highly lipophilic tail [173]. It can 
be used as a stabilizer in cationic liposomal membranes, but its major activity concerns 
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endosomal escape [173].  As the pH drops in the endosome containing a DOPE-liposome, 
it is hypothesized that DOPE displays an inverted hexagonal phase, which in turn 
destabilizes the endosomal membrane [190].  DOPE has been used to deliver Print3G, a 
hydrophilic 25-amino acid antagonist of an oncoprotein involved in breast cancer.  Print3G 
was enveloped in a Stealth ™ pH-sensitive liposome and was able to deliver the peptide to 
the cytoplasm of cancerous cells [173].  While PEGylation reduced the pH dependent 
release, it did not hinder the cytoplasmic delivery of the liposomal cargo [191]. 
 
Micelles 
Due to their large size, liposomes may have difficulty reaching the desired site of 
action, as the liposome may be larger than the vascular cutoff size in certain tumors [192]. 
If this is the case, micelles may be a better alternative.  A study by Weissig et al. 
demonstrated this by comparing micelle and liposome protein delivery side-by-side in a 
Lewis lung carcinoma mouse model.  The PEG-micelle delivered more of the therapeutic 
protein at the desired site than did the long-circulating PEG-liposome [193].  Micelles, 
however, have inherent problems that may prevent them from being used in the delivery 
of therapeutic proteins including low drug loading capacity, low stability in water 
(especially when diluted), short half-life in biological environments, and possible in vivo 
toxicity [194].   
 
Nanoparticles 
Nanoparticles play a role in the protection and delivery of peptides in systemic 
circulation as well.  One example, the carbon nanotube, is well-studied and has been used 
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to deliver proteins [195].   A 2005 study by Wong and colleagues allowed for the pro-
apoptotic protein cytochrome c (cyt-c) to spontaneously adsorb onto carbon nanotubes. 
The nanotubes were then incubated with a variety of cell lines, and the nanotubes were 
taken up via energy-dependent endocytosis.  Once in the cell, cyt-c was released from the 
nanotube and caused increased apoptosis over the empty control nanotube [195].  It has 
been consistently reported that "well processed, water-soluble nanotubes exhibit no 
apparent cytotoxicity to all living cell lines investigated thus far, at least in the timeframe 
of days" [196]. In general, carbon nanotubes have a high propensity to cross cell membrane 
with the apparent mechanism being passive and endocytosis independent [197, 198].  A 
proposed mechanism for cell entry is similar to that of nanoneedles, where the 
nanoparticles perforate and diffuse through the lipid bilayer without causing damage or 
death to the cells [198].  However, nanoparticle targeting is not optimal, and nanoparticles 
often have poor tumor and tissue penetration.  The EPR effect may also be overstated; thus 
passive targeting of nanoparticles is not as good as once thought [199].   
Functionalized nanoparticles have been used to deliver antibodies, active proteins, 
and epitope peptides to the immune system [198, 200]. A recent study revealed new details 
on the mechanism of protein release from protein-loaded nanoparticle systems.  The release 
of protein from an aliphatic polyester-based nanoparticle system was caused by bulk 
degradation of the nanoparticle.  Moreover, intramolecular transesterification was followed 
by hydrolysis of the polymers, which caused the degradation [201].   Further, lyophilizing 
nanoparticles lead to a higher burst release of protein (40-50%) compared to 
nonlyophilized nanoparticles (10-20%).  The authors concluded therefore that freeze-




Many types of nanoparticles other than carbon nanotubes have been used in 
systemic drug delivery.  A type of nanoparticle made of a PCL-PEO combination was able 
to demonstrate increased accumulation at the tumor site as well as reduced clearance by 
macrophages of the liver, thus increasing the possibility of the nanoparticle taking 
advantage of the EPR effect [202].   
 
Cell-Penetrating Peptides 
While increased systemic circulation time and cargo stability are important factors, 
all of this is futile if the therapeutic is not internalized into the cells of interest.  A promising 
and adaptable system for increased internalization is cell penetrating peptides (CPP). CPPs 
are short, water soluble, polybasic peptides with a net positive charge at physiological pH 
[203].  CPPs are able to penetrate cell membranes at low micromolar concentrations while 
not causing significant membrane damage [203].  The internalization method of these CPPs 
and their covalently attached cargo is still being debated; there is evidence of both energy 
independent internalization and endocytosis as the mechanism of internalization.  It is 
currently believed that endocytotic entry followed by endosomal escape is the most 
common entry pathway [204, 205].  The endocytotic pathway is further broken down to 
include macropinocytosis and receptor-mediated endocytosis [204].  While receptor 
mediated endocytosis relies on clathrin, caveolin, or both for internalization, 
macropinocytois may be internalized regardless of cell receptor status [204]. 
CPPs do have a number of pitfalls, one of which is their stability in serum-
containing media [206-209]. Serum proteases may inactivate the cell-penetrating peptide 
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itself, or the attached cargo before the complex is able to reach its target and cross the cell 
membrane [209].  Further, the cationic nature of most CPPs results in aggregation with 
negatively-charged serum proteins [206, 207].  The use of nonnatural amino acids and 
cyclization of the CPP have been utilized to improve the stability of the CPP [208, 210], 
but stability in serum and in vivo models is still problematic.  Details on preclinical and 
clinical trials using CPPs will be discussed in Chapter 5. 
 
Hydrocarbon Stapling 
 As mentioned in the introductory chapter, α-helices are common protein secondary 
structures that have important roles in protein-protein binding [211].  However, α-helices 
tend to lose their structure when in isolation, which can affect their binding affinity [212].  
One of the earliest attempts to stabilize α-helices utilized lactamization between lysine and 
glutamic or aspartic acid to create an intramolecular amide bond [211].  Indeed, this so-
called ‘lactam staple’ resulted in increased helicity of a model hydrophobic peptide [213].  
Blackwell and Grubbs were the first to implement ruthenium-catalyzed ring closing 
metathesis (RCM) stapling to stabilize peptides (Figure 2.5a)[214, 215]; briefly, Blackwell 
and Grubbs substituted two O-allyl serine at i, i+4 spacing into a hydrophobic heptapeptide, 
and covalently joined these UAAs via RCM [214].   With this proof-of-concept study in 
hand, Schafmeister and Verdine created the first all-hydrocarbon stapled peptide utilizing 
Blackwell and Grubbs’s ruthenium- catalyzed ring-closing metathesis (RCM) [216].  After 
incorporating α,α  disubstituted unnatural amino acids (UAAs)  one (i,i+3 or i,i+4) or two 
(i,i+7)  (Figure 2.5b) helical turns apart, the Verdine group optimized the stereochemistries 





Figure 2.5. Innovative peptide stapling chemistries. A) Peptide stapling scheme 
implemented by Grubbs and Blackwell. B) First all-hydrocarbon peptide staple. C) 






peptides demonstrated increased helicity and up to 50 times greater proteolytic resistance 
over unmodified peptides [216].   
Since this work was first published in 2000, the annual number of papers on stapled 
peptides continues to grow, with 35 stapled peptide studies published in 2015 (Figure 2.6).  
Hydrocarbon stapling has been shown to increase target affinity (5-5000 fold), improve 
cell permeability via pinocytotic uptake, and grant strong protection against proteolysis 
[51, 53, 217]. To date, stapled peptides have been investigated for targeting both intra- and 
extracellular targets.  Some notable intracellular stapled peptide targets under investigation 
include p53/MDM2, BH3 domains/MCL-1, axin/β-catenin, and E1/CD81 in hepatitis C 
[218] [219-223].  Extracellularly, stapled peptides have been utilized to target and inhibit 
ABC transporters, estrogen receptors, and have even been utilized in the creation of a long-
acting growth hormone-releasing hormone  (GHRH) analogue, which underwent a Phase 
1 clinical trial in 2013 (results not disclosed). [217, 222, 224]. 
Beyond a variety of targets, the field of stapled peptides has also expanded the 
chemistry of stapling techniques.   Many early adaptions to stapling chemistry are 
considered ‘one component’ staples.  One component staples usually require nonnative 
amino acids which bear functional groups which are joined to create the staple (Figure 
2.7a) [211].  The requirement of UAAs means these peptides must be synthesized, which 
practically limits production to peptides of a maximum 30-50aa in length [225].  While the 
length and chemical identity of the staple can be altered, this must be done by altering the 
UAAs, which can be challenging [211, 217]. Two-component systems involve a 
bifunctional linker compound which is ligated to the peptide and itself becomes the staple 
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Figure 2.6. Stapled peptide annual publication count. Number of annual ‘stapled 


















Figure 2.7. One- and two-component peptide stapling. Representation of one-
component (A) and two-component (B) peptide stapling.  2B shows the favorable, stapled 









and can allow for rapid screens to optimize staple chemical makeup and length without 
needing to alter the peptide itself [211].  However, it is also possible for the peptide to react 
with two separate staple molecules at the staple sites (Figure 2.7b), a side-reaction that is 
not possible in one-component systems.  Table 2.7 includes the characteristics of some of 
the most commonly used stapling techniques. 
Thiol-ene peptide stapling, first published by Wang and Chou in 2015, utilizes the 
well-known thiol-ene click reaction (Figure 2.8) to staple cysteine-containing peptides 
[225, 226].  Importantly, as the stapling can be done off the thiol groups of cysteines, this 
method does not require UAAs.  Stapling off cysteines theoretically allows for the stapling 
of recombinant (rather than synthesized) peptides, which opens the door to stapling larger 
peptides and proteins.   In this work, the researchers tested various reaction conditions, 
staple length, and chemical makeup and the resulting peptide helicity, proteolytic 
resistance, and in vitro activity [225].  Importantly, this reaction was shown to be specific 
for thiol groups, even when other functional groups (such as amines, alcohols, and 
carboxylic acids) are present [225]. Further, Wang and Chou created a thiol-ene stapled 
version of Walensky and Verdine’s p53-MDM2/MDMX inhibitor that was able to 
recapitulate everything seen with the RCM stapled peptide (helicity, proteolytic resistance, 
cell internalization, inhibition of p53-MDM2/MDMX interaction, and apoptosis induction) 
[225].  The relatively long length of CCmut3 (72aa) protein meant it was ‘un-stapleable’ 
with older techniques.  However, as this thiol-ene stapling does not require UAAs and 




























Figure 2.8. Thiol-ene stapling reaction scheme.  A peptide containing two cysteines is 
combined with the radical initiator 2,2 dimethoxy-2-phenylacetophenone (DMPA) in the 
organic solvent N-methyl-2-pyrrolidone (NMP). Irradiation results in radicalization of the 
sulfur in cysteine. This radical reacts with the alkene-containing staple, and the free radical 










 To date, there exist no ‘hard and fast’ rules regarding stapled peptide design; 
researchers are regularly surprised, often unpleasantly, by the helicity, permeability, and/or 
binding affinity of their stapled peptides.  However, certain guidelines on design have been 
developed over the last 15 years.  First, the staple should either be opposite (fully solvent 
exposed) or adjacent (partially solvent exposed)  to the binding interface, as to not sterically 
interfere with binding [229].  Interestingly, some partially exposed staples have been 
shown to themselves participate in target binding via van der Waals contacts, as seen with 
some of the BH3 mimetics [229]. Adjacent stapling also decreases the entropic penalty of 
solvation for the hydrocarbon, which may aid in aqueous solubility [229, 230]. 
Second, as all stapling reactions to date require specific amino acids at stapling 
sites, critical interacting residues should not be replaced.   The goal is to decrease the 
entropic cost of binding by locking the peptide in its α-helical conformation without 
negatively affecting the enthalpy of binding.  Towards this same goal, UAA selection, 
stereochemistry, and linker length have been optimized for RCM.  For i,i+7 staples, R,S or 
S,R stereochemistries for the UAAs are most commonly used along with an 11-carbon 
linker [229].  Staple length will have to be optimized independently for each of the staples 
to be used in two-step reactions, although the size of the linkers is generally comparable to 
those in RCM reactions [211, 217, 225, 229].  The Verdine group recently published a new 
technique known as ‘peptide stitching’, which creates a stapled peptide  i, i+7, i+11 – that 
is, there are two hydrocarbon staples, both sharing an anchor point on a disubstituted UAA 
at the i+7 position.  Optimal UAA stereochemistry and hydrocarbon linker lengths for 
peptide stitching are similar to those of standard peptide stapling [231, 232]. 
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 Computational modeling is commonly utilized in the design of stapled peptides.  
As it can be expensive (in time and money) to synthesize, staple, and test the activity of 
stapled peptides, any method that can reduce the frequency of inactive peptides is useful.  
Energy minimization, the simplest and fastest of the commonly used computational 
techniques, can determine comparative energy minima of different stapled peptides.  
However, this method requires a priori knowledge of the peptide’s structure in solution.  
Further, the simulations cannot calculate energy minima for conformations grossly 
different from the starting conformation, another limitation [229].  Monte Carlo 
simulations work similarly, but they generate an ensemble of conformations by making 
random changes to the positions of atoms at each step, which allows this simulation to 
sample conformations that are quite different from the starting conformation [229].  
Finally, Molecular dynamics (MD) simulations  integrate Newton’s equations of motion to 
describe the “temporal evolution of a set of interacting atoms”[229] .  MD is quite accurate 
at predicting peptide helicity, which is extremely useful at the early stages of a project [229, 
233, 234]. 
As the majority of stapled peptides have been designed to inhibit intracellular 
protein:protein interactions, cell penetration of stapled peptides is prerequisite to their 
function.  Although much work has been done to determine the exact mechanism of cell 
permeation by stapled peptides, it is not yet known [230, 232].  The process is known to 
be clathrin- and caveolin-independent endocytosis, although the peptides appear to exploit 
an as-of-yet uncharacterized pathway [235]. However, cell surface proteoglycans are 
thought to be involved [232].  Certain characteristics such as α-helicity, overall charge, 
hydrophobicity, staple composition and placement affect stapled peptide internalization 
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have been understood to play a role in stapled peptide internalization, but until recently, 
the exact contribution and importance of each was unknown.  The Verdine group recently 
tested over 200 stapled peptides which cover a large range of all of the aforementioned 
characteristics [232].  They found that a formal charge between 0 and +2 was optimal for 
nondamaging cell penetration.  Although larger positive formal charges corresponded with 
greater peptide internalization, they also are linked to membrane damage [232].  The 
Walensky group carried out their own analysis and found that staple location (partially 
solvent-exposed), and helical content are the best predictors of stapled peptide membrane 
penetration sans membrane disruption as tested by electron microscopy and lactate 
dehydgogenase assays [217, 230].  Stapled peptides with approximately 60-90% helicity 
and pIs between 8.8 and 9.3 demonstrated optimal cellular uptake.  However, Walensky et 
al. found little correlation between formal charge and cell penetration for stapled peptides, 
and found that large positive charge and higher pI (greater than 9.7) are associated with 
membrane damage [230].  Further, these peptides cross the cell membrane without damage 
and efficiently escape the endosome [231] .  This may not be surprising, as the first stapled 
peptide against an intracellular target that has made it to clinical trials has a net charge of -
1 [236].  A clearer picture of the pro-internalization characteristics may become clearer as 
more stapled peptides are created with variations in all of the aforementioned 
characteristics. 
 
Targeting and Membrane Permeation 
CPPs are a versatile tool which can be used for increased internalization of 
liposomes, nanoparticles, or proteins themselves [237-239].   CPPs have been extensively 
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researched as supplements to liposomes, and a few issues have been uncovered.  First, 
CPPs like Trans-activating transcriptional activator, TAT, are susceptible to enzymatic 
cleavage by plasma enzymes when they are on the surface of liposomes [237].  Also, CPP-
modified liposomes can cause severe toxicity and are rapidly cleared from the blood and 
accumulate in the kidney and liver; therefore, PEG modification is often necessary when 
using CPPs with liposomes [240-243].  Unfortunately, PEGylation of CPP-modified 
liposomes appears to decrease the effectiveness of the CPP [244].  TAT and arginine-rich 
CPPs have been used to target the kidney and spleen, respectively [245, 246].  One study 
demonstrated that R8 (8 arginine repeat) modified lipid nanoparticles were able to 
efficiently deliver cargo (in this case siRNA) to the cytosol of cells in the liver [247].  
Further, hydrocarbon stapling of CPPs increases their stability and cell permeability [232]. 
CPPs have also been directly conjugated to proteins for delivery in vivo and in vitro 
[248-253].  One successful example of in vivo use delivered a single chain antibody Fv 
fragment to tumors, resulting in a decrease in tumor volume and neovascularization [251]. 
Targeted CPPs have also been discovered and designed.  The specificity is often gained 
via activation of the CPP in the tumor environment or by conjugating a targeting moiety to 
the CPP [254-256].  Selectivity can also be obtained by having a homing motif in the CPP 
sequence; Nishimura et al. have discovered a CPP screened by phage display that 
selectively transduces leukemia cells [257]. The CPP consists of a lymph-node homing 
motif (CAY) and the CPP motif (RLRR), with the full sequence being CAYHRLRRC 
[257].  This CPP is currently being utilized in our lab to deliver a protein therapeutic for 
CML therapy.  CPPs are appealing, as they may be able to increase the delivery of protein 
therapeutics through the cell membrane, escape from endosomes, and get into the 
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cytoplasm of the desired cells.  Table 2.8 provides a representative example from a variety 
of CPP classes. 
Antibodies are another modification strategy which has been implemented to 
increase the targeting ability of liposomes and nanoparticles.  One study by Kirpotin and 
colleagues demonstrated that monoclonal antibodies (MAb) directed against the HER2 
receptor increased the cytoplasmic delivery of the liposomes contents [258].  Interestingly, 
in this study the MAb did not alter the biodistribution of the liposome, but rather increased 
MAb-mediated endocytosis which increased drug delivery to the cytoplasm.  Similar 
methods have been used with PLGA nanoparticles [259].  Researchers were able to 
demonstrate in vitro selectivity and increased internalization of the MAb-adsorbed 
nanoparticles [258].    As both liposomes and nanoparticles can be loaded and/or coated 
with therapeutic peptides, targeting via antibodies can lead to increased peptide delivery to 
a specific site or cell type.  The conjugation and adsorption of antibodies to liposomes and 
nanoparticles is a promising field; further research will likely produce translatable results 
which will aid in the targeting of therapeutics. 
 
Conclusions and Future Perspective 
While proteins and peptides have immense therapeutic potential, delivery and 
systemic stability currently limit their clinical use.  The oral route is appealing, as it is a 
simple and often cheap route of delivery.  Couple this with reduced consumption of the 
supplies needed for invasive delivery (IV, IM, SubQ, etc.), and it is easy to see why patient 
compliance is highest for orally delivered drugs.  Peptides and proteins are readily 




Table 2.8. Sample CPPs and their applications in peptide delivery.  This table contains 
representative CPPs which represent the major classes of targeted and untargeted CPPs.  
TAT and Penetratin are generally untargeted, although their biodistribution may cause site-
selective accumulation.  LS-CPP is a leukemia-specific CPP.  The tumor prodrug CPP is 
cleaved at the “/” when in the tumor environment, thus separating the negatively charged 
amino acids from the positively charged CPP-cargo conjugate.  Antibody-targeted CPPs 
can be used to selectively deliver a CPP-cargo conjugate to desired cell types. 
CPP: Cell-penetrating Peptide; Tat: trans-activating transcriptional activator; LS-CPP: 
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movement across the epithelial barrier.  Advances in the oral delivery of proteins and 
peptides have been made by the use of absorption enhancers, enzyme inhibitors, and direct 
structural modification of the therapeutic.  Mucoadhesive polymers, nanoemulsions, and 
nanoparticles have been utilized to increase the stability of peptides as well as increase 
their absorption.  However, as of yet no generalizable strategy for the delivery of peptide 
and protein therapeutics has been found; many of the strategies in this paper were 
customized to the peptide being delivered, as the complex nature and variety of peptides 
and proteins makes this difficult.  Work on generalizable peptide delivery systems is 
ongoing; both the GI-MAPS and SNAC systems show encouraging data and appear to be 
well suited to deliver a large range of peptides.  With all of these systems, however, safety 
and efficacy questions loom large.  Long-term safety has not been studied, and safety issues 
have arisen even with the short-term use of some of the compounds discussed in this 
review.  
By delivering drugs transdermally, issues with GI stability can be avoided, but 
absorption still poses problems.  Systems developed to overcome the barriers posed by the 
skin include microneedle technology, thermal ablation, electroporation, sonophoresis, and 
iontophoresis.  Each of these systems was designed with patient comfort and ease of use in 
mind.  Despite some successes with transdermal delivery, most of the systems above have 
not been used to deliver therapeutic peptides or proteins to humans; further development 
and study in this area is necessary.  While peptide delivery by other noninvasive routes 
(pulmonary, intranasal, buccal, rectal) is being studied, other reviews provide a more 
complete coverage of these topics. 
After a peptide therapeutic enters the systemic circulation, it must remain active 
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and reach the correct site/cell type in the body.   Direct peptide modifications, liposomes, 
and nanoparticles are used to increase stability while the addition of antibodies and CPPs 
are used for targeting and to supplement cellular delivery.  Endosomal escape, which 
threatens to inactivate the therapeutic peptide at the last stage, has also had some promising 
advances.  It is important to note that some of the methods which increase systemic stability 
are not currently amenable to oral delivery (e.g., liposomes). 
Peptide and protein therapeutics, with their high target specificity and broad 
applicability, have the potential to revolutionize medical therapy.  Clearly, there are still 
challenges to overcome in each of the areas discussed.  Optimally, in the future there will 
be a system that can be used for the oral delivery and systemic stability of a variety of 
peptides and proteins.  As delivery and systemic stability are two overarching issues with 
protein and peptide therapeutics, overcoming these would likely lead to even further 
development of peptide and protein therapeutics with great therapeutic potential.   
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This dissertation has focused on advancing our rationally designed, Bcr-Abl 
dimerization inhibitor from gene therapy to a deliverable protein therapeutic.  Unlike 
conventional CML therapies that target the Bcr-Abl tyrosine kinase domain, we aim to 
inhibit Bcr-Abl dimerization, a prerequisite to activation of the tyrosine kinase in Bcr-Abl.  
Past studies by Lim lab alumni Drs. Andrew Dixon and Geoffrey Miller created an 
optimized dimerization inhibitor, CCmut3, which favors binding to Bcr-Abl and disfavors 
binding to itself.   The next step towards creating a CCmut3 therapeutic was to create a CCmut3 
protein capable of crossing cell membranes while maintaining activity (CPP-CCmut3, 
Chapter 3).  After this success, we focused on further modifying CCmut3 to improve its 
proteolytic stability. To this end, in collaboration with the Chou group, we utilized a novel 
method of stapling, which for the first time allowed the stapling of recombinant proteins.  
While we were able to staple full-length CCmut3, the resulting proteins were more sensitive 
to proteolysis than their unstapled counterparts.  Possible alternate strategies to overcome 




Basics and Recent Advances in Peptide and Protein Drug Delivery 
 Today, there are more than 100 approved peptide/protein-based therapies on the 
market in the U.S.[1].  These large molecules can be highly selective for their target, much 
more so than the small molecules that have dominated medicine since time immemorial 
[1].  However, these peptide therapeutics face a number of unique problems, including low 
bioavailability, proteolysis (both in the GI and circulation), and limited cell penetration [2].  
Cyclization, PEGylation, protease inhibitors, D-amino acids, and absorption enhancers 
have all been utilized to improve the oral bioavailability of peptide and protein 
therapeutics, with some successes [1, 3-8].  Beyond direct structural modifications, 
liposomal and nanoparticle delivery systems have been developed to increase the oral 
bioavailability [9, 10]  and systemic resistance to proteolysis and opsonization [11, 12] 
[13].   
 Creating a protein therapeutic that is stable in circulation is, unfortunately, only half 
of the battle.  The targets for many of these drugs are intracellular, meaning the protein 
therapeutic must cross the cell membrane.  To that end, fusogenic liposomes [14] as well 
as compounds meant to help the protein therapeutic escape the endosome and subsequent 
degradation have been developed [14-19].  
Of particular interest to this dissertation are cell penetrating peptides (CPPs) and 
peptide stapling. CPPs are short, water-soluble, polybasic peptides with a net positive 
charge that are able to penetrate cell membranes at low micromolar concentrations without 
causing membrane damage.  Importantly, the CPP can be ionically or covalently linked to 
cargo – whether it be a peptide, protein, or small molecule [20-22].  Hydrocarbon stapling 
is a technique used to stabilize α-helical proteins, improve target affinity, cell penetration, 
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and serum stability [23-25]. Recent advances now allow for the stapling of recombinant 
proteins, whereas until recently only those peptides made by SPSS could be stapled [26].  
Peptide and protein therapeutics, with their high target specificity and broad 
applicability, are already revolutionizing medical therapy.  Clearly, there are still 
challenges to overcome in each of the areas discussed. As delivery and systemic stability 
are two overarching issues with protein and peptide therapeutics, overcoming these would 
likely lead to even further development of peptide and protein therapeutics with great 
therapeutic potential.   
 
Inhibition of Bcr-Abl with a Coiled-Coil Protein Delivered via LS-CPP 
Since the first cell-penetrating peptide (CPP) was discovered in 1988, many 
researchers have utilized CPPs to improve the intracellular delivery of protein therapeutics 
[27].  Of interest to this dissertation is the work by Nishimura and Kuniyasu which utilized 
phage display to isolate peptides that selectively internalize in leukemia and lymphoma 
cells [28].  We utilized this leukemia-specific cell-penetrating peptide (LS-CPP) for the 
selective delivery of CCmut3 to leukemic cells.  CPP-CCmut3 was expressed, purified, and 
tested for its antioncogenic activity.   Three purification schemes were unsuccessfully 
attempted (data not shown) before the successful purification scheme (Chapter 3) was 
optimized.  After purity was demonstrated by SDS-PAGE analysis, the identities of the 
purified proteins were verified by mass spectroscopy.    
Next, both leukemic (K562, Ba/F3) and nonleukemic (HEK-293, MCF7) cells were 
treated with CPP-CCmut3 and controls.  As expected, this cell penetrating peptide delivered 
the constructs preferentially to leukemic cells, and those protein constructs lacking the CPP 
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did not enter any of the cell lines tested. CPP-CCmut3 had antioncogenic activity in Bcr-
Abl+ leukemia cell lines K562 and Ba/F3 p210, but not in the Bcr-Abl-, pro-B cell line 
Ba/F3 (as evidenced by 7-AAD/Annexin V, colony forming assay, cell proliferation, and 
Bcr-Abl phosphorylation).  This lead construct has two built-in safeguards against 
nonspecific toxicity.  First, CCmut3 was shown to be nontoxic in Bcr-Abl- cell lines (Figure 
5.1, unpublished data, collected by Dr. Andrew Dixon).  These assays were carried out 
with CCmut2, an earlier iteration of our dimerization inhibitor which differs from CCmut3 by 
one amino acid (K39E).  Second, the LS-CPP will deliver the therapeutic preferentially to 
leukemic cells.  Toxicity aside, unmodified CCmut3 would likely be sensitive to proteolysis 
in vivo, and attempts to ameliorate this problem are discussed in Chapter 4. 
 
Stapling of Full-Length CCmut3 
Since all-hydrocarbon stapling of peptides was first pioneered by Schafmeister and 
Verdine in 2000 [29], α-helical peptide stabilization has become an exciting arena, and 
some stapled peptide therapeutics are even being tested in clinical trials [25, 30, 31].  
However, most stapling chemistries require the incorporation of UAAs at the stapling sites 
(Table 2.7).  Currently, incorporating UAAs into peptides requires that the peptide must be 
chemically synthesized, which limits the size of the peptide to 30-40 aa. As CCmut3 is 72 
aa, stapling of full-length CCmut3 was unfeasible. Serendipitously, the Chou group 
(Biochemistry, University of Utah) developed a stapling scheme which required only 
cysteines at the staple site, thus removing the UAA requirement and associated peptide 
length  limitations.  Through  mutagenesis,  CCmut3  was  modified  to  include  two  (single 






Figure 5.1 CCmut construct is nontoxic to Bcr-Abl- cell lines 1471.1 and Cos7.  Data 










was to be used in this reaction.  Unfortunately, miscibility issues (CCmut3- hydrophilic, 
staple- hydrophobic) made this impossible.  Therefore, the more hydrophilic (and untested) 
diallylurea staple was used.  The stapling reactions were optimized, and single stapled (SS) 
and double stapled (DS) versions of CCmut3 were characterized by LC/MS, circular 
dichroism, and SDS-PAGE.   
Following confirmation of the identity and alpha-helicity, stapled and unstapled 
(SS-U, DS-U) proteins were treated with three proteases: trypsin, chymotrypsin, and 
endoproteinase GluC.  Surprisingly, the stapled proteins were more susceptible to 
proteolysis than both CCmut3 and cysteine-substituted, unstapled proteins SS-U and DS-U.  
Despite altering reaction conditions and attempting to control for all confounders, this 
result held.  Further, mass spectroscopy analysis of digested SS and DS denoted rapid 
proteolysis of the proteins in all regions except those covered by the staple.   Both native 
PAGE and size-exclusion chromatography suggest the stapled proteins exist in two 
conformations – one has approximately the same hydrodynamic radius as unmodified 
CCmut3, while the other is about half the size as CCmut3.   
With this information, we hypothesize that the hydrophilic CCmut3 may refold to 
bury the relatively hydrophobic DAU staple when in aqueous solutions.  Historically, 
hydrocarbon stapling has been performed on shorter, hydrophobic peptides [32].  The size 
and hydrophobicity of these peptides means there is little entropic penalty for solvating the 
additional hydrophobic staple.  However, there is an entropic penalty for solvating the 
relatively hydrophobic DAU on the hydrophilic CCmut3, and the increased length of CCmut3 
means it may be able to refold and bury this hydrophobic patch, resulting in altered protein 
conformations.  Computational modeling (performed by Sean Cornillie, Cheatham lab) 
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supports this conclusion, although exactly how the altered protein conformation results in 
increased sensitivity to proteolysis remains unclear.  
Future computational modeling which analyzes the change in helicity of the 
proteins as a function of time could help to answer this question.  Specifically, if our 
hypothesis is correct, we expect to see the stapled proteins demonstrate periods of 
decreased helicity (compared to unstapled control), during the time course of the 
simulation.  The protein would be more susceptible to proteolysis when it loses its 
structure.  A more detailed analysis of the phi-psi angles of the protein over the timecourse 
of the simulation could also add to our understanding of the increased proteolysis of the 
stapled proteins.  More specifically, the simulations would focus on the torsion angles of 
the amino acids at and near the predicted protease cleavage sites.  Previous computational 
and biological work has identified the required torsion angles/conformations required for 
protease-protein docking [33-35].  If our hypothesis is correct, we would expect the 
modeling to show the stapled proteins adopted these torsion angles more frequently 
compared to the unstapled proteins.  Unfortunately, due to the constraints of collaborators 
and availability/cost supercomputer time to run these complex simulations, these 
simulations were not run.   
 
Future Directions 
 Before discussing the future directions of this project, a brief overview of our initial 
attempt at making a stapled peptide is in order. As stated previously, classical hydrocarbon 
stapling requires the incorporation of UAAs, and therefore necessitates SPSS.  To meet the 
requirements of SPSS, the Lim and Cheatham labs designed a stapled peptide version of 
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helix 2 of CCmut3 (aa 28-67).  Computational modeling by Sean Cornillie and Dr. Thomas 
Cheatham revealed that, while truncating CCmut3 down to helix 2 reduced binding affinity 
with CCwt, double hydrocarbon stapling these peptides restored the binding affinity to 
above that of full-length CCmut3:CCwt (Figure 5.2). Truncating CCmut3 to just helix 2 
decreases the enthalpy of binding, but this loss is overcome by the reduced entropic cost 
of binding, as the peptide is already locked into its alpha helical conformation [36]. 
Based on these results and theoretical protection from proteolysis, we initiated a 
collaboration with the Walensky group (Harvard), and purchased three double-stapled 
helix 2 peptides at cost.  These peptides each have two staples: 29/36-50/57 (St. #1), 30/37-
50/57 (St. #2), and 29/36-43/50 (St. #3).  The peptides were delivered with LC/MS data 
and a declaration that the proteins were >90% pure.  Based on this information, I first tested 
to see if these stapled peptides could cross cell membranes. The peptides were fluorescently 
labeled, and therefore fluorescence intensity correlates with cell permeability.  While all 
stapled peptides were able to enter K562 leukemic cells, stapled peptide #1 appears to 
demonstrate superior cell permeability (Figure 5.3, n=2). 
Confocal microscopy was then performed to determine the location of the stapled 
peptides.  A  red  membrane dye  (Cell  Mask  far-red  membrane dye, ThermoFisher) was 
used to stain the cell membrane.  After a 4-hour incubation and washing with trypsin, 
heparin, and PBS, the stapled peptides appear to be associated with the membrane (Figure 
5.4A).  However, after the cells were allowed to grow for an additional 24 hours, the stapled 































Figure 5.3. Stapled peptide internalization in K562 cells.  Cells were treated in serum-
free media, and at the indicated time, cells were washed to remove any membrane-bound, 
noninternalized peptide.  Cells were then analyzed by flow cytometry, and FITC intensity 
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Figure 5.4. K562 cells treated with stapled peptide. #1 were imaged (A) immediately 
after a 4-hour incubation in serum-free media and washes and (B) 24 hours after the start 
of incubation, or 20 hours after washing the cells. The stapled peptide is membrane-
associated at T=4, while at T=24 the stapled peptide appears to be truly intracellular. Red 










With these data in hand, we proceeded to test the antioncogenic activity of the 
stapled peptides.  For this purpose, 7-AAD, Annexin-V, MTT, colony forming and cell 
proliferation assays were performed. In all of these assays, surprisingly, none of the stapled 
peptides had any effect as compared to untreated cells (Figure 5.5). The positive control, 
small-molecule imatinib, demonstrated antioncogenic properties, as expected. 
Following these results, we ran native PAGE with fluorescent imaging 
(Figure5.6A) and dynamic light scattering (DLS, Figure 5.6B) to determine if these 
peptides were forming aggregates.   The native PAGE showed much of the proteins were 
stacking at the top of the gel, a sign of aggregation.  Further, rather than one, clean band, 
the gel revealed a ‘smear’ of fluorescence, indicating the samples were not pure.  Following 
this result, the peptides were analyzed by DLS.  While controls (silver nanoparticles and 
albumin) appeared to be the appropriate size, all three stapled peptides appeared to be 
aggregating, with stapled peptide #1 forming the largest aggregates.  
At this point, the purity/identity of the provided samples was in doubt.  Therefore, 
the stapled peptides were analyzed via LC/MS.  Figure 5.7 shows the LC data provided by 
the Walensky lab (A) and the report from our core facility (B). Whereas the LC plots from 
the Walensky group only denote one major peak and high sample purity, the LC data from 
the University core facility indicate there are numerous species in the samples.  When 
discussing these results with Dr. Krishna Parasawar, co-director of the mass spectroscopy  
core, he stated these samples were well below 50% pure.  It should be noted that, prior to 
LC/MS analysis, the peptides had been stored as lyophilized powder, and desiccated at -20 
ºC, meaning the samples were impure when received from the Walensky group.  With this 








Figure 5.5. Stapled peptide antioncogenic activity.  None of the stapled peptides 
demonstrated any antioncogenic activity in the K562 human leukemia cell line.  Assays 
included 7-AAD and Annexin V for apoptosis induction, colony forming assay for 















Figure 5.6. Analysis of stapled peptides by native PAGE and DLS.  The native PAGE 
(A) indicates impure and aggregating samples, while DLS (B) confirms the stapled 















Figure 5.7. LC/MS analysis of stapled peptides. A. Data provided by the Walensky 
group. B. Data from Utah Mass Spectroscopy core facility.  The red boxes in (B) indicate 







As mentioned in Chapter 4, immiscibility meant CCmut3 could not be stapled with 
an all-hydrocarbon staple.  Peptide stapling is generally carried out in organic solvents, and 
the Chou lab was unable to dissolve CCmut3 in any hydrophobic solvents.  The grand 
average of hydropathicity (GRAVY) is a measure of the overall hydrophobicity of a 
peptide.  Most proteins found in nature range from -2 (hydrophilic) to +2 (hydrophobic) 
[37].  The GRAVY of full-length DS-U (CCmut3 with 4 cysteines) is -0.897, whereas the 
truncated helix 2 is more hydrophilic, -1.087 (as reported by the ProtParam tool on 
Expasy.org).  Therefore, in retrospect, we handed the Walensky group the difficult (if not 
impossible) task of stapling a hydrophilic peptide with an all-hydrocarbon staple.   
One important take-home message here is that the truncated, stapled helix 2 (the 
stapled peptides from the Walensky group) has not been properly tested, since we received 
an impure sample that was impure and prone to aggregation.  As previously mentioned, 
the failure of stapled, full-length CCmut3 (Chapter 4) may be partially due to its size and 
ability to re-fold and bury the staple. Therefore, it may be possible to staple helix 2 with 
DAU or another, relatively hydrophilic staple.  The log(p) of 1,8 nonadiene, a staple used 
by Walensky is 4.6, while DAU has a log(p) of 0.6.   
The original modeling for the all-hydrocarbon stapled peptides (performed by Sean 
Cornillie) only looked at the constructs when bound to their target, CCwt.  Cornillie recently 
modeled the truncated, hydrocarbon-stapled peptides unbound in aqueous solution.  
Perhaps not surprisingly, the peptide folded in such a way to bury the hydrophobic staples 
(Figure 5.8A).  This analysis was repeated with DAU-stapled helix 2, and the results were 
similar (Figure 5.8B).  Therefore, even if the protein is truncated down just to helix 2, 







Figure 5.8. Computational modeling of stapled helix 2. (A) all-hydrocarbon stapled 














staple molecules with varying hydrophobicity, and those staples that do not show the sort 
of protein folding seen below can be created and tested. 
Alternatively, full-length CCmut3 could be stapled with a more hydrophilic staple 
than DAU.  For instance, the Wang and Chou attempted to use the compound 1,2-bis(4,5-
dihydro-1H-imidazol-2-yl)propan-2-yl)diazene dihydrochloride as the staple in their 
original thiol-ene stapling work [26].  According to Molinspiration’s log(p) calculator, this 
compound is more hydrophilic than DAU, and therefore may be better suited as a staple 
for CCmut3.  Alternatively, a charged linker could be used, although care must be taken, as 
this added charge may affect the cell penetration of the stapled protein.  However, as the 
vast majority of stapled peptides use all-hydrocarbon or (at least) very lipophilic staples, 




Sortase Ligation of a Cell-Penetrating Peptide and St-CCmut3  
 
While using a hydrophilic staple may help maintain the secondary structure of 
CCmut3, it may also reduce cell penetration.  The internalization capacity of stapled peptides 
is thought to be  due in part to the  hydrophobicity  of the hydrocarbon staple [32]; as Dr. 
Greg Verdine stated, “if you were an amphipathic α-helix bearing an all-hydrocarbon 
staple, would you prefer to live in aqueous culture medium or head to a lipid 
membrane[25]?”  A possible solution is to include the LS-CPP (utilized in Chapter 3) to 
improve  the delivery  of  the  stapled, stabilized CCmut3.  The  sequence of the  LS-CPP is: 
CAYHRLRRC.   
The cysteines in this CPP would likely cause problems during the stapling process, 
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as the Chou lab’s technique adds a staple between two cysteine residues.  Therefore, this 
CPP could be added to the peptide after the stapling reaction is completed.  Specifically, 
CCmut3 was designed with an N-terminal triglycine sequence which can be used for sortase 
ligation [38].  Indeed, the Chou lab has successfully ligated the LS-CPP and CCmut3; 
however, this work was performed on unstapled CCmut3 (data not shown).  Another option 
is to use a different CPP, one without any cysteines present, to avoid the need for sortase 
ligation.  As the Chou lab’s current optimum conversion of CCmut3 to CPP-CCmut3 is quite 
low, near 20% (personal communication, Maria Disotuar, Chou lab), eliminating the need 
for this step would increase our final yield 5-fold.  However, the leukemia-specific CPP is 
preferred, as it may decrease protein delivery to nonleukemic cells, thus reducing the 
required dose. Secondly, the LS-CPP cyclizes via formation of a disulfide bridge between 
two cysteines.  As noted in Chapter 2, cyclic peptides tend to be more stable than their 
linear counterparts [39].   For these reasons, the cyclic, leukemiaspecific CPP is preferred 
to other nonspecific CPPs such as TAT or penetratin.  
While CPPs are often successful in vitro, less success has been seen with systemic 
in vivo studies as well as in clinical trials.  As of late 2016, 15 clinical trials using CPPs 
have been performed.  However, only 2 of these are phase III clinical trials [40].  Further, 
nearly all clinical trials using CPPs are concerned with local (rather than systemic) delivery 
of a therapeutic peptide or protein.  For instance, a c-Jun N-terminal kinase inhibiting 
peptide, known to reduce inflammation [41], was delivered via TAT using intraocular 
injection in an attempt to reduce postoperative intraocular inflammation in a phase III trial 
(results not yet published).  The same process was used for intratympanic delivery for the 
treatment of acute hearing loss, with clinical benefits seen in a phase II trial (phase III trial 
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is currently recruiting) [42]. 
 The systemic delivery of a therapeutic peptide via CPP was carried out in two phase 
I clinical trials.  p28 is a 28 amino acid peptide known to penetrate cells and decrease the 
ubitquination of p53, and thus may be beneficial to treat those with p53+ tumors (by 
increasing the half-life of the antiapoptotic protein p53) [43].  While the trials showed it 
was well tolerated even at maximal doses, there was minimal evidence of antitumor 
activity, even at cumulative doses up to 140mg/kg over a 48-week period.  For a 70kg 
adult, this equates to 10 grams of protein over the treatment course.   For comparison, the 
recommended dose of adalimumab is 40mg every 2 weeks, or just over 1 gram per year.  
When one considers the molar differences in the drugs (2.9 kDa vs. 150kDa), the molar 
dose of p28 needed for the year of therapy is about 150x that of adalimumab.  As CPPs 
require relatively high concentrations to trigger internalization, systemic treatment via CPP 
may require unrealistically high doses, considering the cost of biologicals today. 
Regardless of the cause, most CPP-based therapies falter in phase I/II trials, even those 
only aiming for topical or local delivery [40]. 
 
Protein Carrier Systems 
While Chapter 2 covers many possible protein delivery modifications/systems, 
nearly all are impractical for the delivery of our therapeutic CC protein.  First, we anticipate 
I.V. delivery of our protein, so none of the systems/modifications meant to increase oral 
stability/absorption need be considered.  Further, most of the systems discussed in the 
‘systemic peptide stability’ section aim for longer circulation time of the nanoparticle, 
resulting in controlled release of the protein therapeutic (e.g., liposomes, micelles, and 
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carbon nanotubes).  As CPPs require high concentrations for internalization, the 
aforementioned systems are an irrational choice.  Therefore, alternative systems aimed at 




As discussed in Chapter 2, PEGylation of proteins has the potential to improve the 
pharmacokinetic properties of the protein drug, such as increased half-life, reduced 
immunogenicity, and improved resistance to proteolysis [13, 44-46].  It is thought that 
PEG, which has a large hydrodynamic radius, shields the protein from proteases and 
antibodies [47, 48]. However, care must be taken when choosing a site to PEGylate; not all 
PEGylated proteins have the improved characteristics described above.  Further, the 
specific conjugation strategy and linker characteristics alone can greatly alter the stability 
of PEGylated peptides and proteins [49].  In particular, cysteine-based PEGylation 
strategies confer less PK benefit than others (amide and triazole-based approaches), which 
is thought to be related to the relative flexibility of cysteine linkers [49].  Therefore, simply 
substituting cysteines at preferred PEGylation sites may not be the optimal strategy for 
stabilizing CCmut3.  While proteins can be PEGylated at the primary amine of lysine [50], 
that CCmut3 contains 5 lysines makes this approach impractical for our purposes.  Other 
conjugation strategies are generally site-restricted (N- or C-terminus), nonspecific 
(glutamine-based) or require UAAs (Asn-PEGylation, azide- or alkyne- containing 
UAAs), and therefore are not be applicable or optimal for CCmut3 modification [49]. 
However, PEGylation may increase circulation time at the cost of reduced target 
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affinity [46, 51, 52].  For example, when Stigsnaes and colleagues PEGylated the α-helical 
peptide glucagon they noted it demonstrated improved biochemical stability, but 
PEGylation simultaneously disrupted the α-helical structure of the peptide [53].  Beyond 
the site chosen, the length and branching of the PEG chain used also affects conformational 
stability [49, 54], and this is an area of ongoing research. As an example, PEGylating the 
alpha-helical HIV-1 fusion inhibitor gp41 at the c and f sites of the heptad repeat (away 
from the binding interface, Figure 5.9) minimized loss of binding affinity, although the 
lead construct still saw a 2.7-fold reduction in binding affinity when compared to wild-type 
gp41 [51].  While PEGylation can reduce the binding affinity of the protein, increased 
serum half-life and plasma residence time can counteract this loss of affinity, resulting in 
greater in vivo activity [51].  Dual-PEGylation of two  sites which independently provide 
improved PK profiles on one peptide can lead to synergistic, additive, or antagonistic 
effects [44].  Overall, PEGylation of CCmut3 has the potential to result in a bioactive, stable 
protein, although obtaining this construct would require extensive optimization and testing. 
 
Nanoparticles 
 Nanoparticles have been used for the systemic protection and delivery of protein 
therapeutics [55]. However, they still face many problems  including opsonization, cellular 
internalization, endosomal escape, and drug efflux pumps [56].  Despite these problems, 
10 liposome-drug systems have been approved by the FDA [56].  Liposomal delivery of 
our CCmut3 construct is possible, and would require extensive liposome optimization in 
order to create stable, biocompatible liposomes with appropriate release kinetics.  PLGA 










Figure 5.9. Coiled-coil helical wheel diagram.  Residues in the heptad repeat are 
assigned a position: a and d are typically the hydrophobic amino acids leucine, 
isoleucine, valine and e and g are typically charged amino acids.  Dimerization is driven 
by hydrophobic interactions of a and d residues as well as ionic interactions between g 












protection  of  the  protein  therapeutic requires  harsh reaction conditions to synthesize the 
nanoparticle, which may in itself inactivate the protein therapeutic [46].  Gold 
nanoparticles are another attractive delivery option.  These nontoxic and inert particles are 
relatively easy to synthesize, and can be readily functionalized through thiol linkages which 
can be tuned for intracellular drug release [58].  Indeed, gold nanoparticles have 
successfully been used for proteolytic protection of therapeutic proteins as well as the 
intracellular delivery of peptides, proteins, and nucleic acids [58, 59].  However, again it 
is difficult to engineer the particle surface for optimal therapeutic protein binding and 
release, bioavailability, and nonimmunogenicity [58].  Each of the systems discussed (and 
the multitude not mentioned) requires extensive optimization.  While potentially viable as 
alternative options for the delivery of CCmut3, it is beyond the scope of this dissertation. 
 
Dual Target Therapy 
 As was shown by Dr. Geoffrey Miller, CCmut3 has additive (if not synergistic) 
effects when used in combination with the TKI ponatinib [60].  This study should be 
repeated with stapled CCmut3, once a functioning construct is created.  The work by Miller 
showed that, not only does simultaneously targeting two domains of Bcr-Abl have a greater 
therapeutic effect, but the required dose of ponatinib is reduced nearly 10-fold.  Second 
and third generation TKIs  have many off-target effects, and these effects are believed to 
be dose-dependent [61, 62].  In particular, ponatinib use is associated with an increased 
risk of cardiovascular events in a dose-dependent manner [63], which has been linked to 
ponatinib’s potent inhibition of VEGFR signaling pathway [62].  Therefore, reducing the 
dose 10-fold (as seen in Miller’s combinatorial therapy work), could reduce the 
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cardiotoxicity associated with ponatinib use.  Another possibility is dual Bcr-Abl targeting 
with stapled CCmut3 and the allosteric inhibitor ABL001.  As dual therapy with ABL001 
and nilotinib reduced tumor regressions in mice [64], a dual (or possibly triple) therapy 
with ABL001 and stapled CCmut3 could have a similar effect.  
 
Use of CCmut3 in Bcr-Abl-Independent Resistance 
Bcr-Abl independent resistance has been associated with genetic variabilities in 
drug import and efflux [65-67], epigenetic modifications/upregulation of HDACs [68, 69],  
and the activation of alternative signaling pathways [68].  STAT3 has recently been 
implemented as a key mediator of Bcr-Abl independent resistance, and the Deininger group 
has successfully screened and tested a STAT3 inhibitor + imatinib, a combination that is 
synthetically lethal to CML progenitor cells that display Bcr-Abl independent resistance 
[70, 71].  Beyond synthetic lethality, the STAT3 inhibitor restored TKI sensitivity to cell 
lines that previously demonstrated Bcr-Abl independent resistance [70].  However, if the 
patient is unlucky enough to have both Bcr-Abl independent resistance AND a TKI-
untreatable compound mutant (e.g., E255V/T315I) this combination therapy will likely not 
work.  Studies performed by Drs. David Woessner and Geoffrey Miller showed CCmut3 is 
effective against mutant Bcr-Abl, including the compound mutant E255V/T315I [60, 72].   
Therefore, a combination of CCmut3 + STAT3 inhibitor may have a place in therapy.  
Further, as many stem cells are insensitive to TKIs [73, 74], a therapy aimed at Bcr-Abl 






Materials and Methods 
 
Cell Culture and Transfections 
 
K562 cells were cultured as in [75].  Cos-7 and 1471.1 cells were cultured and 
transfected as in [76].  Cos-7 and 1471.1 cells grow as monolayers in DMEM and RPMI 
(GIBCO, Invitrogen, Carlsbad, CA, USA), respectively, both supplemented with 10% FBS 
(Hyclone Laboratories, Logan, UT, USA), 1% penicillin-streptomycin (GIBCO), 0.1% 
gentamicin (Hyclone), and 1% L-glutamine (Hyclone). The cells were maintained in a 5% 
CO2 incubator at 37 °C. 1471.1 cells were grown to approximately 50% confluency, and 
5 x 106 cells in 100 μL cold plain DMEM were transiently cotransfected via electroporation 
as previously described (22, 23). Transfections were performed using the Electrosquare 
Porator ECM 830 (BTX, Harvard Apparatus, Holliston, MA, USA) with 2 μg of EGFP-
protein switch plasmid and 2 μg of DsRed plasmid along with 6 μg pGL3basic (Promega, 
Madison, WI, USA) carrier DNA for a total of 10 μg DNA. Three pulses of 140 V were 
applied for 10 msec. Following the electroporation, the cells were plated in complete 
DMEM in a 2-well live cell chamber (Lab-tek II chamber slide system, Nalge NUNC, 
Rochester, NY, USA), and incubated in a 5% CO2 incubator at 37 °C overnight. Cos-7 
cells were seeded into a 2- or 4-well live cell chamber 24 hrs prior to transfection with 
Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) so the confluency was around 90% 
on the day of the transfection. Transfections were carried out as recommended by the 






Stapled Peptide Internalization 
Cells were treated with peptides washed as in [75]. Flow cytometric analysis was 
performed on a FACSCanto II analyzer (Becton Dickinson, Franklin Lakes, NJ, USA) 
using BD FACSDiva v6.13 software.  Excitation and emission filters were as follows: 
FITC, 488nm excitation, emission filter 500-560. Laser intensity was held constant 
between samples and replicates.  
 
Stapled Peptide Activity Experiments 
K562 cells were treated with peptides as in [75].  7-AAD, Annexin V, colony 
forming  assays, and cell  proliferation assays were  performed as in [75].  MTT assay  was  
carried out as in [72]. 
 
Native PAGE 
Protein constructs (either alone, or in combination as noted in the image) were 
diluted to a concentration of 10µM in PBS.  Samples were then run on Novex tris-glycine 
4-20% gels with Novex tris-glycine native sample and running buffers.  Gels were imaged 
using the Typhoon fluorescent gel imager (GE Healthcare), as in [78].   
 
Confocal Microscopy 
Following incubation of cells with peptides, cells were washed to remove bound, 
noninternalized peptide as in [75].  All images of K562 live cells were acquired on an 
Olympus IX81 FV1000-XY spectral confocal microscope (Imaging Core Facility, 
University of Utah) equipped with 405 nm diode, 488 nm argon, and 543 nm HeNe lasers 
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using a 60X PlanApo oil immersion objective (NA 1.45) using Olympus FluoView 
software. Excitation and emission filters were as follows: EGFP, 488 nm excitation, 
emission filter 500-530 nm; Cell Mask far-red membrane dye (ThermoFisher), 633 nm 
excitation, emission filter 555-655 nm. Images were collected in sequential line mode with 
exposure , and no channel crosstalk was observed. Pixel resolution was kept at 1024 x 1024 
(0-2.5-fold digital zoom) with a pixel dwell time of 12.5 µs. 
 
LC/MS 
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